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List of abbreviations in order of appearance 
NAFLD: Non-alcoholic Fatty liver disease 
NASH: Non-alcoholic steatohepatitis 
SS: Simple steatosis 
AUROC: Area under the receiver operating characteristic curve  
PNPLA3: patatin-like phospholipase domain containing 3 
TM6SF2: transmembrane 6 superfamily 2  
FGF21: fibroblast growth factor 21  
HCV: Hepatitis C virus 
SRTR: Scientific Registry of Transplant Recipients 
Mm: Millimetres 
CRP: C-reactive protein 
TNF-α: Tumour necrosis factor alpha 
FFAs: Free fatty acids  
ROS: Reactive oxygen species 
IR: Insulin resistance 
GGT: Gamma-glutamyl transpeptidase 
AST: Aspartate transaminase 
ALT: Alanine transaminase 
NAS Score: NAFLD Activity Score 
SAF Score: Steatosis Activity and Fibrosis Score 
NASH-CRN: NASH Clinical Research Network  
NIH: National Institutes of Health 
US: Abdominal ultrasound 
CT: Computed tomography 
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MRI: Magnetic resonance imaging 
PDFF: Proton density fat fraction 
MRE: Magnetic resonance elastography 
MRS: Magnetic resonance spectroscopy 
TE: Transient elastography 
CAP: Controlled attenuation parameter 
ARFI: Acoustic Radiation Force Impulse 
CK-18: Cytokeratin-18 
mRNA: Messenger RNA 
NFS: NAFLD Fibrosis Score 
PPV: Positive predictive value 
NPV: Negative predictive value 
APRI index: AST to Platelet Ratio Index 
UPLC-MS: ultraperformance liquid chromatography coupled to mass spectrometry 
GWAS: Genome-wide associations studies 
SNPs: Single nucleotide polymorphisms 
HTGC: Hepatic triglyceride content 
1H-MRS: proton magnetic resonance spectroscopy  
CRF: Case report form 
BMI: Body mass index 
HDL-c: High-density lipoprotein cholesterol 
LDL-c: Low-density lipoprotein cholesterol  
Rpm: Revolutions per minute  
ELISA: Enzyme-linked immunosorbent assay  
SSFSE-T2: Single Shot Fast Spin Echo T2-weighted 
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FoV: Field of view 
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qRT-PCR: Quantitative real-time polymerase chain reactions 
RIN: RNA Integrity number 
SD: Standard deviation 
ROC: Receiver operating characteristics 
OR: Odds ratios 
kg/m2: Kilograms per square meter 
Se: Sensitivity  
SP: Specificity  
mmol/L: Millimoles per litre 
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Non-alcoholic fatty liver disease (NAFLD) has become one of the top concerns for 
the practising hepato-gastroenterologist due to the obesity epidemic and its potential to 
progress to an advanced liver disease that significantly impacts on overall and liver-related 
mortality. Due to the rapidly advancing epidemics of obesity and diabetes, a large segment of 
the population is at risk for NAFLD. Particularly worrisome is the emergence of NAFLD or 
non-alcoholic steatohepatitis (NASH) with a significant fibrotic disease in developing 
countries, even in patients of normal or underweight. 
A critical issue in patients with NAFLD is the differentiation of NASH from simple 
steatosis (SS). It is then of particular importance to identify NASH patients as they are at 
greatest risk of developing cardiovascular diseases and complications such as cirrhosis, liver 
failure or hepatocellular carcinoma. 
There is a need, in NAFLD management, to develop non-invasive methods to detect 
NASH and to predict advanced fibrosis stages. Therefore, we evaluated the following items: 
 (i) A tool-based on optical analysis of liver magnetic resonance images as biomarkers 
for NASH and fibrosis detection by investigating patients with biopsy-proven NAFLD who 
underwent magnetic resonance protocols using 1.5T General Electric or Philips devices. Two 
imaging biomarkers (NASHMRI and FibroMRI) were developed, standardized and validated 
using the area under the receiver operating characteristic curve (AUROC) analysis. The 
results indicated NASHMRI diagnostic accuracy for steatohepatitis detection was 0.83 
(95%CI: 0.73-0.93), and FibroMRI diagnostic accuracy for significant fibrosis determination 
was 0.85 (95%CI: 0.77-0.94). These findings were independent of the magnetic resonance 
system used. We conclude that the optical analysis of magnetic resonance images has high 
potential to define non-invasive imaging biomarkers for the detection of steatohepatitis 
(NASHMRI) and the prediction of significant fibrosis (FibroMRI). 
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 (ii) Genetic and epigenetic biomarkers, such as human patatin-like phospholipase domain 
containing 3 (PNPLA3), transmembrane 6 superfamily 2 (TM6SF2) and fibroblast growth 
factor 21 (FGF21) variants as well as a panel of most abundant liver microRNAs. After 
univariate and multivariate analysis, we confirmed that GG genotype of PNPLA3 exerted a 
clear role in NASH development, and we identified the impact of a novel risk variant located 
in FGF21 gene in significant fibrosis stages. Besides, we found overexpression of FGF21 
levels in both liver and serum, directly related to NASH condition. Finally, two microRNAs 
(miR-200b-3p and miR-224-5p) were screened and validated in human liver tissue and 
plasma of biopsy proven NAFLD patients, and were found raised in NASH, conferring them 
potential as non-invasive biomarkers. 
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1.1 Non-alcoholic fatty liver disease concept, epidemiology, comorbidities, 
complications, and pathophysiology 
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of 
hepatic disease worldwide, and its rates are growing together with metabolic syndrome. It has 
been considered not just the hepatic manifestation of metabolic syndrome in the liver but also 
a key factor in the development of complications related to metabolic syndrome (1). 
This disorder is usually classified into two different phenotypes, simple steatosis (SS) and 
non-alcoholic steatohepatitis (NASH), accompanied with various fibrosis stages. This entity 
comprises a broad spectrum of lesions ranging from simple steatosis to steatohepatitis 
(defined by inflammation and ballooning). These patients could show fibrosis progression to 
cirrhosis, being at risk of potentially life-threatening liver-related complications, such as 
hepatocellular carcinoma, cirrhosis decompensation or requiring orthotropic liver 
transplantation (2). Cirrhosis describes the fibrosis or scarring that occurs as part of a wound 
healing response to non-alcoholic steatohepatitis, which is commonly called NASH (figures 1 
and 2). 
 
Figure 1. Non-alcoholic fatty liver disease spectrum. 
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In fact, the increased incidence of NASH and fibrosis has been found directly related 
to a raised mortality and morbidity. Besides, NAFLD is becoming the leading cause of liver 
transplantation for both end-stage liver disease and hepatocellular carcinoma in the United 
States (3). Hence, if the current rates of obesity and diabetes continue for another two 
decades, the prevalence of NAFLD in the world is expected to increase by 50% in 2030, 
leading to an epidemic of NAFLD. 
The dogma supporting that NASH patients but not simple steatosis were at risk of 
liver disease progression seems to be controversial (4, 5). Patients suffering from simple 
steatosis trend to progress to NASH and to develop fibrosis in paired liver biopsies during 
short-term follow-up between 3 to 6 years. Together to the risk of fibrosis progression sample 
error should be kept in mind. Further, fibrosis staging in NAFLD showed a good concordance 
between pathologists but fibrosis distribution in the liver is heterogeneous, and it could be 
found different stages of fibrosis in the same liver, in the same patient. Thus, it is mandatory 
to segregate patients according to NASH presence but also close monitoring it using non-
invasive methods to classify patients according to the risk of progression. Metabolic 
syndrome, hyperinsulinemic state, and diabetes seem to belong to the most dangerous 
phenotype implicated in disease progression (6). However, hyperlipidaemia and obesity seem 
to be more heterogenic influencing on disease progression. Interestingly, men are at higher 
risk of having severe fibrosis compared to women, at least before menopause. 
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Figure 2. A healthy liver (1) can progress to fat accumulation (2) and then to NASH, which 
features inflammation (3), cell swelling (4), and sometimes scarring (5) (7). 
 
Patients with NASH-cirrhosis are at risk to develop complications and outcomes such 
as hepatocellular carcinoma or cirrhosis decompensation. In comparison with hepatitis C-
related (HCV) cirrhosis, NASH-cirrhosis showed a lower rate of cirrhosis decompensation 
mainly in ascites development. Hepatocellular carcinoma rate has been estimated in 0.67% 
cases per year in NASH-cirrhotic in comparison with 1.7% per year in HCV-cirrhosis (8). 
Patients suffering from NASH-cirrhosis showed higher mortality due to cardiovascular 
disease. Changes in hepatic blood flow in NAFLD patients occurred during the earliest stages 
of fibrosis due to the outflow block in the sinusoidal area, as well as increased splenic 
stiffness (9). Moreover, according to the SRTR (Scientific Registry of Transplant Recipients) 
in United States, NASH-related cirrhosis is currently the third most common indication for 
liver transplantation overtaken by hepatitis C virus and alcoholic cirrhosis (10). 
NAFLD is closely associated with features of metabolic syndrome, such as abdominal 
obesity, atherogenic dyslipidaemia, hypertension, insulin resistance and impaired glucose 
tolerance. The majority of patients showing NAFLD has, at least, one of these characteristics 
and up to one-third can present the whole syndrome (11). Thus, this entity shares multiple 
potential risk factors with cardiovascular disease (12).  
Interestingly, cardiovascular disease is the main cause of complications in NAFLD. In 
fact, several meta-analyses have reported this association (13). By contrast, chronic liver 
disease is the responsible for most of morbidity and mortality in NASH stage (14). A routine 
assessment of the cardiovascular risk seems to be adequate in patients with NAFLD. To reach 
this aim, several non-invasive methods have been proposed. Firstly, carotid disease is an 
independent entity that can predict stroke (15) and cardiovascular events (16). To evaluate 
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carotid disease, we can measure carotid intima-media thickness and the presence of carotid 
plaques by ultrasound. A thickness > 9 millimetres (mm) is considered pathological. This test 
seems to be the most used in NAFLD patients. Secondly, the number of coronary artery 
calcifications is directly related to cardiovascular events. This evaluation is performed by 
computerized tomography (17). Thirdly, left ventricular hypertrophy has been reported to 
increase the number of cardiovascular-related events and can be easily diagnosed by 
electrocardiogram and echocardiogram (18). Fourthly, there are tests whose aim is to detect 
blood vessel abnormal function. In particular, ankle-brachial pressure index identifies the 
presence of peripheral arterial disease and flow-mediated dilation detects endothelial 
dysfunction (19). Lastly, biomarkers (i.e. C-Reactive Protein (CRP) or Tumour Necrosis 
Factor alpha (TNF-α)) could be a good option to evaluate the cardiovascular risk although 
they need to be more extensively validated. 
Recent data from both human and animal studies support the concept that the 
hepatocellular injury that characterizes NASH is mainly driven by the overload of primary 
metabolic substrates, such as glucose, fructose and fatty acids in the liver, leading to a 
diversion of fatty acids into different pathways that could promote different cellular injuries 
and a dysfunctional response to that damage. Anyway, various aspects of those pathways 
leading to both NASH and liver fibrosis vary among patients, as this is considered a 
multifactorial entity  (20, 21). Pathogenesis of the illness is unclear with the most widely 
supported theory implicating insulin resistance and impaired lipid metabolism that leads to fat 
accumulation in the liver, as the fundamental mechanisms. Some researchers also support that 
a second hit, or additional oxidative injury, is required to manifest the necroinflammatory 
component of steatohepatitis; this results from a combination of mitochondrial dysfunction, 
oxidative stress, lipid peroxidation, hormonal abnormalities and cellular toxicity from free 
fatty acids (FFAs)  (22). Mitochondrial dysfunction is also crucial in the pathogenesis of 
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NAFLD leading to overproduction of reactive oxygen species (ROS) that promote hepatocyte 
injury. Oxidative stress triggers cell membrane peroxidation, cell degeneration and apoptosis, 
and the expression of pro-inflammatory and pro-fibrogenic cytokines leading to progressive 
liver damage. NAFLD/NASH is considered as a chronic inflammatory disease, while 
cytokines have been linked to the development and prognosis (figure 3). 
 
 
Figure 3. NASH pathogenesis model. 
 
1.2 Management and care of patients with NAFLD 
 
Management of non-alcoholic fatty liver disease (NAFLD) in clinical practice is a 
current and permanent challenge. The main aim is to segregate patients according to risk for 
disease progression keeping in mind both endpoints, liver and cardiovascular diseases. 
Patients referred for NAFLD study usually show hiperechogenicity of the liver in 
ultrasonography or increased transaminases together with features of metabolic syndrome. In 
non-hyperechogenic liver, suspicion should be delayed to demonstrate negative etiologic 
study. 
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Monitoring of these patients is mainly based on the histological findings and the 
associated diseases. There are three key areas to consider in handling NAFLD patients:  
a) Lifestyle modifications, including diet and exercise (23),  
b) Drugs targeting the components of metabolic syndrome and  
c) Managing of liver disease outcomes (24).  
The optimal strategy remains unclear, but patients with NASH and fibrosis require 
more intensive lifestyle modifications and liver–directed pharmacotherapy, and if it fails, 
they need to be included in clinical trials. 
Family history is an essential part of our routine medical evaluation and contains 
information on fatty liver, obesity, and diabetes. Indeed, several studies have shown familial 
clustering of NAFLD as well as its severity, especially in settings of coexisting insulin 
resistance (IR). In non-diabetic patients with NASH, a family history of diabetes could be 
found in more than 40%, and these patients showed increased risk of fibrosis progression. 
Patient history should include central obesity, type 2 diabetes, dyslipidaemia, and 
hypertension to recognize metabolic syndrome. Also, evidence of menopausal status, biliary 
gallstones, obstructive sleep apnoea syndrome, hyperuricemia, hypothyroidism, growth 
hormone deficiency, and polycystic ovary syndrome should be recorded.  
Dietary habits using a diary recording adherence to Mediterranean diet and industrial 
fructose consumption; one protective and the other promoter of NASH risk. It is also 
mandatory to exclude excessive alcohol consumption by interview and analysis of 
biochemical variables including increased gamma-glutamyl transpeptidase (GGT) levels, 
aspartate/alanine transaminases (AST/ALT) ratio, mean corpuscular volume of erythrocytes, 
and carbohydrate-deficient transferrin levels (25). The average alcohol consumed (in grams) 
per day should be recorded. Alcohol consumption thresholds to define non-alcoholic nature 
of the steatohepatitis include < 21 units of alcohol per week for men and 14 units of alcohol 
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per week for women over a 2-year time frame before evaluation. One unit of a standard drink 
is equivalent to a 12-ounce beer, 4-ounce glass of wine, or one-ounce shot of distilled liquor. 
The significant social and economic impact across Europe means that effective management 
strategies NAFLD are urgently needed.  
1.3 Current diagnosis: liver biopsy assessment 
 
The current gold standard method for the assessment of hepatic fibrosis and NASH 
relies on liver biopsy, although its confirmed limitations include bleeding, perforation, death, 
and a high cost. These drawbacks imply several obstacles for the viability of clinical trials. 
Monitoring the natural progression of NAFLD by histology could generate a disproportionate 
number of liver biopsies compared to the rate of patients who develop severe complications.  
Histopathological criteria for NASH diagnosis have changed over time, wherein 
fibrosis presence is not required for the diagnosis. Pathological classifications utilised are 
Matteoni classification (26), Brunt classification (27), NAFLD Activity Score (NAS) (28) 
and, most recently, Steatosis Activity and Fibrosis (SAF) Score (29, 30) (tables 1 and 2)  
Moreover, it has been established hepatocellular ballooning as a key histological 
finding in NASH diagnosis, being a component of common NAFLD scores. Ballooned 
hepatocytes frequently contained Mallory-Denk bodies, and the main mechanisms implicated 
in ballooning degeneration are basically, rearrangement of intermediate filament 
cytoskeleton, accumulation of small-droplet fat in the cytoplasm and endoplasmic reticulum 
dilatation. All these mechanisms support a key role of ballooning on disease progression (31). 
In an elegant study by Ratziu et al., 51 patients underwent two liver biopsies that were scored 
separately. Steatosis, ballooning, inflammation and fibrosis seem not being equally 
distributed across the liver. In 21 out of 51 cases one stage difference in fibrosis was seen, 
and ballooning has been observed in just one liver biopsy in 9 out of 51. Thus, fibrosis stage 
variability was found around 40% and ballooning diagnosis around 20%. All these aspects 
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should be taken into account when analysing paired liver biopsies for disease progression or 
histological response (32). 
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Table 1. NASH Clinical Research Network (NASH-CRN) scoring systems definitions. 
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Table 2. SAF Score diagnostic algorithm for NASH.  
 
 
1.4 Non-invasive diagnosis of NAFLD 
 
Due to this increasing burden, there is an urgent need for reliable and accurate non-
invasive methods to stage the disease, as well as identification an outburst of potential 
innovative therapeutic targets to inhibit the progression and associated risks of this disease. 
Among the top diagnostic concerns are the detection of NASH and liver fibrosis, as they have 
both been proven to increase the risk of mortality related to both liver and cardiovascular 
diseases (33, 34). Early detection of fibrosis and cirrhosis is essential due to the 
complications derived from these conditions, such as hepatic encephalopathy or gastro-
oesophageal varices. Therefore, an urgent demand for reliable and accurate non-invasive 
approaches is emerging.  
The epidemic of NAFLD/NASH is a clear threat to public health and healthcare 
systems. There are gender and ethnic differences, the latter possibly attributed to different 
lifestyle and dietary patterns, insulin resistance, adiposity distribution and genetic variations. 
To date, various non-invasive biomarkers have been identified; however, they lack accuracy, 
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especially in certain sub-populations, and usually, need external validation before being 
applied in clinical practice. 
Further, NAFLD is a multifactorial disease affected by both environmental and 
genetic factors, and its precise pathogenesis is still not fully understood. According to the 
National Institutes of Health (NIH) definition-working group, the description of a biomarker 
(35) is a characteristic that is objectively measured and evaluated as an indication of normal 
biologic processes, pathogenic processes or pharmacological responses to a therapeutic 
intervention. To our understanding, the ideal test should be economical, widely accepted, 
bias-free, and reflective of the biological phenomenon studied and validated through 
sensitivity, specificity, and predictive capacity (figure 4).  
Screening biomarkers to detect susceptibility, together with prognostic biomarkers for 
disease progression, and finally, response biomarkers to therapy could improve the 
management of NAFLD. The successful search of a new biomarker depends on strengthen of 
the definition of the end-point, the more accurate end-point, the better biomarker. The main 
features of a biomarker include from A to F: Acceptability; Bias of process selection of the 
candidate; Cost of tests; Diagnostic accuracy; Errors measurement and Feasibility. They 
should demonstrate ability to predict baseline presence of NASH and fibrosis stage together 
with the possibility of detecting NASH resolution and fibrosis regression after therapeutic 
intervention. The most important aspects included in the validation process comprise:  
(i) Content validity, the biomarker should reflect the biological process studied,  
(ii) Construct validity, in the disease manifestation and  
(iii) Criterion validity, the biomarker correlates with the particular disease and 
should be measured by sensitivity, specificity, and predictive power.  
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Figure 4. Cluster of biomarkers according to FDA/NIH. 
 
Following the EASL guidelines, in order to reduce the number of liver biopsies, non-
invasive markers should aim to:  
i) In primary care settings, identify the risk of NAFLD among individuals 
with increased metabolic risk,  
ii) In secondary and tertiary care settings, identify those with worse prognosis, 
e.g. severe NASH,  
iii) Monitor disease progression and  
iv) Predict response to therapeutic interventions (36).  
 
This epigraph will be divided into the three primary categories of non-invasive 
assessment of NAFLD: imaging, biochemical and genetic biomarkers (figure 5).  
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Figure 5. Non-invasive approaches spectrum for NAFLD diagnosis. 
 
1.4.1. Imaging biomarkers 
 
Significant improvements have been made in the field of imaging techniques, placing 
them as highly accurate diagnostic tools, with strong potential for NAFLD detection. 
Abdominal ultrasound (US) is used as a routine first-line screening, diagnosis, and follow-up 
of NAFLD patients. Among the main features of NAFLD is hiperechogenicity, increased 
liver size, vascular blunting or attenuation of the ultrasound wave (37). However, this method 
is operator-dependent, and when fat infiltration is less than 30%, US is unable to detect 
steatosis, and the sensitivity of this technique ranges between 60-84%, and the specificity is 
among 84-95%, which increases in parallel of the severity of steatosis (38).  
Computed tomography (CT) could be used to diagnose steatosis by comparing spleen 
and liver attenuation values but is not sensitive stratifying and detecting fibrosis stage. CT is 
also unable to detect steatosis when there is less than 30% of fat in the liver (39). 
Additionally, it exposes patients to radiation, and therefore its use for NAFLD detection is 
less common. 
Magnetic resonance imaging (MRI) techniques can quantify both fat and liver 
fibrosis. Hepatic steatosis is commonly measured by evaluating the proton density fat fraction 
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(PDFF) and has been validated across various sub-populations, demonstrating that several 
confounding factors, such as age, sex, body mass index and disease components have no 
substantial impact on its diagnostic accuracy. This technique also offers an excellent 
reliability and reproducibility, also responding to changes over time (40). However, this 
approach still has several restrictions, such as the small portion of the liver analysed, the 
expertise needed to acquire and quantify the images and its high running cost. Regarding fat 
evaluation, multi-echo MRI fat fraction has also been proposed as an attractive tool to 
determine the hepatic lipid concentration in NAFLD obese patients (a specific subpopulation 
especially hard to diagnose) (41). Other novels MRI techniques have been developed to 
quantify the main features of this disease. 
Retrospective and prospective studies reported that magnetic resonance elastography 
(MRE) has shown a high diagnostic accuracy in staging fibrosis in NAFLD patients, specially 
diagnosing advanced fibrosis stages, such as F3-F4, independently of BMI and inflammatory 
status (42), but not for NASH. Furthermore, in a recent study carried out in more than 100 
liver biopsy-proven NAFLD patients, MRE was found to be more accurate than transient 
elastography identification of liver fibrosis, from stage 1 of the disease (43).  Lastly, liver 
stiffness measured by MRE has been shown to have high accuracy as defined by the area 
under the receiver operating characteristic curve (AUROC = 0.93) for discriminating patients 
with NASH from those with SS, with 94% sensitivity and 73% specificity (44). 
Magnetic resonance spectroscopy (MRS) detects small quantities of fat as it identifies 
spectral peaks at resonance frequencies precise to the protons in triglycerides. Recent studies 
on cellular based-metabolism biomarkers in high-fat diet rats for non-invasive steatosis 
assessment (45), by hyperpolarized 13C magnetic resonance spectroscopy, suggested the 
potential use of MRS for steatosis diagnosis. The main limitation of this study was the small 
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number of animals included, which was six rats per group, and the fact that metabolic 
changes were measured only from a single localized voxel.  
Liver stiffness measurement has been widely utilized in chronic viral hepatitis and has 
been extrapolated to NAFLD. Transient elastography (TE), brand named FibroScan, has been 
used to measure liver stiffness in NAFLD patients, and seems to be accurate enough to 
predict the stage of fibrosis, showing an AUROC higher than 0.83 (46). Nevertheless, these 
results can be influenced by obesity and the degree of steatosis, leading to potentially false-
positive results (47). Body mass index higher than 28 kg/m2 was related to higher failures 
rate (4.5%). Cut-off values defining fibrotic stages in NAFLD measured by FibroScan® 
varied among the reports (4, 48, 49) and failure rate range from 5% to 19% (50). The new XL 
probe achieves higher successful rates than M probe, although surprisingly, cut-off points 
have been suggested to be lower than those for the M probe (51).  
Recently, a new tool has emerged, provided by the same device, which uses similar 
probes to TE, called controlled attenuation parameter (CAP), capable of detecting hepatic 
steatosis. A recent study designed to evaluate whether the liver stiffness could be influenced 
by CAP measurements, suggested that CAP values should always be considered to avoid 
overestimation of liver fibrosis when assessed by TE (52). However, a recent cross-sectional 
study has demonstrated that MRE and PDFF showed higher diagnostic accuracy in liver 
fibrosis and steatosis detection in comparison to TE and CAP methods (53, 54). 
Finally, few studies have evaluated the diagnostic accuracy of acoustic radiation force 
impulse (ARFI) in NAFLD patients, trying to differentiate between fibrosis stages (55-57) 
and incorporating patients with morbid obesity (58). The main limitation of this method is the 
narrow ranges for stratification of fibrosis that can difficult an adequate patient management 
in clinical practice. 
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1.4.2. Serum biomarkers  
 
A serum biomarker is a measurable substance that can be used as an indicator of a 
biological condition. Different algorithms of serum biomarkers for fibrosis staging or NASH 
detection include combinations of direct or indirect markers that have been proposed to 
exclude severe disease and risk stratification and to provide valuable prognostic information 
of hepatic and non-liver related comorbidities. Further, several commercial marker panels 
have been evaluated for their ability to distinguish among disease stages, although these 
panels are still limited by their high cost. 
Cytokeratin-18 (CK-18) is a major intermediate filament protein found in the liver, 
which is generated during cell death (M65) or apoptosis (M30). Its secretion into the serum 
makes it a measurable condition. Raised levels of CK-18 are able to distinguish between SS 
and NASH, but currently, the AUROC ranges between 0.71 and 0.93 (59, 60) and are 
associated with fibrosis and inflammation (61).  
Fibroblast growth factor 21 (FGF21) is a member of the fibroblast growth factor 
family that regulates lipid metabolism and reduces hepatic lipid accumulation in an insulin-
independent manner (62). FGF21 is secreted as an endocrine factor to coordinate the adaptive 
response to starvation or fasting, or as an autocrine factor induced in adipose tissue during the 
fed state to regulate adipocyte function (63). FGF21 arbitrates the crosstalk between different 
metabolic organs to regulate glucose and lipid metabolism through pleiotropic actions in 
these tissues and the brain. The liver regulates carbohydrate production through hepatic 
FGF21 generation, suppressing single sugars consumption but not complex carbohydrates, 
proteins or lipids (64). FGF21 has been proposed as a protective factor in metabolic disorders 
in various animal models. Administration of recombinant Fgf21 in diabetic rhesus monkeys 
has revealed potent in vivo benefits on glucose and lipid metabolism, insulin sensitivity and 
body weight without effects on cell proliferation and tumorigenesis (65, 66). Several human 
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studies have reported that circulating FGF21 levels are increased in metabolic syndrome (67), 
obesity (68), type 2 diabetes mellitus (69), hypertriglyceridemia (70) and NAFLD (71, 72). 
Since FGF21 is synthesized in the hepatocyte, it is rational to consider that pathological liver 
alterations could modify its expression. Hereby, FGF21 messenger RNA (mRNA) was found 
increased in NAFLD human liver, but not in NASH (73). This fact could be related to FGF21 
resistance (74). Moreover, treatment with LY2405319, a recombinant variant of FGF21, 
causes significant dyslipidaemia amelioration in obese humans with type 2 diabetes mellitus 
(75). Lately, in a two-stage genome-wide meta-analysis designed to identify common genetic 
variants associated with total energy intake from different sources, a single-nucleotide-
polymorphism (SNP) located in FGF21 gene (rs838133) was related to  decrease the protein 
intake and increase the carbohydrate ingestion (76). 
Other markers of NAFLD hepatocyte inflammation include adiponectin, TNF-α, 
leptin and resistin, associated with obesity-related diseases, such as NAFLD. Various serum 
markers have shown a moderate diagnostic accuracy with an AUROC higher than 0.8. 
Several panels of routinely available serum biomarkers can confirm, or rule out, 
significant fibrosis in NAFLD patients. NAFLD Fibrosis Score (NFS) (77) is a blood test 
specifically designed to evaluate liver fibrosis in NAFLD, with validated diagnostic accuracy 
(78), but according to the two thresholds, this marker still has a grey zone (> –1.455 to < 
0.675), that could reach from 25% to 56% of the cases, thereby a liver biopsy is needed. 
Diagnosis accuracy is high when results are over or under cut-offs defining no advanced 
fibrosis (NFS < –1.455) and advanced fibrosis (NFS > 0.675) (positive predictive value 
(PPV) 82%-90% and negative predictive value (NPV) 88%-93%). However, high NFS levels 
have been associated with raised risk of systemic events, especially cardiovascular 
complications (79).  
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Further, FibroMeter® development was aimed to find a specifically designed NAFLD 
test for significant hepatic fibrosis, but is less sensitive than NFS for advanced fibrosis 
discrimination (80). 
AST to Platelet Ratio Index (APRI index) (81) and Forns score (82) were initially 
developed in patients with chronic hepatitis C but were both represented with a moderate 
diagnostic accuracy when applied in NAFLD (83). On the other hand, FIB-4 test had the 
same initial purpose, but its diagnostic accuracy is similar to NFS in advanced fibrosis 
determination (84). They are routinely used in chronic hepatitis to exclude advanced disease 
because are cheap and easy to perform they have been used in clinical practice. Considering 
the parameters the availability of the lab parameters could be an election method to rule out 
advanced fibrosis, but it was found unable to distinguish among SS and NASH. Further, these 
methods were developed in chronic hepatitis and thresholds could not be transferred to 
NAFLD without previous estimation, validation and standardization process. Sidney’s index 
(85) showed a high potential to exclude advanced fibrosis in chronic hepatitis C, 
incorporating insulin resistance to improve diagnostic accuracy of different biochemical 
methods. BARD score (86) also excludes patients with advanced fibrosis, especially in non-
diabetic populations, and more recently, it has been found useful for excluding liver fibrosis 
in bariatric populations (87). 
Several serum biomarkers have been integrated into mathematical models to generate 
predictive scores. Fibromax® constitutes a quantitative panel of serum biomarkers as an 
association of three tests (Fibrotest®, Steatotest®, and NashTest®) that offers information 
about fibrosis, steatosis, and necroinflammatory activity or NASH (88). It has been validated 
in chronic hepatitis C (89) and steatosis (90). It has been recently reported that FibroTest® 
and Steatotest® have prognostic values for predicting survival in patients with metabolic 
disorders (91). This algorithm combines various clinical and biochemical parameters to detect 
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all the spectra of NAFLD conditions, including steatosis, NASH, inflammation, and fibrosis. 
Although this became very popular and reached important diagnostic accuracy, higher than 
0.83 in every condition (92), it is not easy to perform in clinic, as some of the variables are 
not available in routine lab assays.  
Finally, OWLiver® (93) analyses the metabolic profile of NAFLD patients by 
evaluating 540 serum metabolites using ultraperformance liquid chromatography coupled to 
mass spectrometry (UPLC-MS) to discriminate among SS and NASH. Although the AUROC 
supports a high diagnostic accuracy for NASH according to body mass index (0.85), the main 
limitations are the scarce availability of this technique requiring to be processed in a central 
lab and the inability to distinguish fibrosis. Among all these tests, only NFS and FIB-4 have 
been externally validated more than once in different populations (94).  
 
1.4.3 Genetic and epigenetic biomarkers 
 
In the majority of patients, NAFLD is a multicomponent disease rooted in metabolic 
syndrome features. Due to the substantial variation in terms of disease severity and mortality 
risks, beyond environmental factors, once the complete genome was fully published, a major 
part of the research has focused on genetic implications in each stage of NAFLD 
pathophysiology.  
Genome-wide associations studies (GWAS) have considerably increased the 
knowledge of identifying novel players associated with NAFLD pathogenesis, constituting a 
powerful tool. Among these, single nucleotide polymorphisms (SNPs) have received growing 
attention, revealing new pathogenic loci and generating new biological hypotheses. They 
have been associated with SS and oxidative stress, inflammation, liver fibrosis and lastly, 
hepatocellular carcinoma. Although liver biopsy is still considered the gold standard for the 
evaluation of liver disease, it is still limited by variability and sampling error. Therefore, the 
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incorporation of an unalterable genetic marker for liver fibrosis or NASH to a predictive 
algorithm could provide an increased diagnostic accuracy. 
Epidemiological, familiar and twin studies have provided enough shreds of evidence 
for NAFLD spectra heritability. Different familial clustering studies have demonstrated the 
heritable component of NAFLD. One study conducted on eight kindred showed that at least 
50% of members were affected by various patterns of relatives and conditions (95). 
To this regard, twin studies offer valuable information. In a recent study performed in 60 
pairs of twins, hepatic steatosis and liver fibrosis were found strongly correlated in 
monozygotic twins but not in dizygotic twins, supporting the hypothesis that they are 
heritable traits (96). 
In 2008, Romeo et al discovered a variant in a GWAS performed in a population-
based study where hepatic liver content was measured by magnetic spectroscopy (97). This 
SNP was located in the PNPLA3 gene on chromosome twenty-two, which codes for a protein 
with lipase activity towards triglycerides in hepatocytes. This isoleucine to methionine 
substitution results in a loss of function leading to the accumulation of triglyceride in 
hepatocytes, which in turn effects the development and progression of NAFLD.  Further 
replication studies have shown robust associations between PNPLA3 and steatosis, fibrosis, 
cirrhosis, and hepatocellular carcinom (98), even conferring susceptibility to lifestyle 
modifications (99). 
Subsequently, GWAS revealed other common SNPs associated with fat accumulation 
in liver. Those SNPs could modify or not the aminoacidic sequence, are stably heritated and 
confers susceptibility to disease development or pharmacological or non-pharmacological 
treatment response. More recently a nonsynonymous single nucleotide polymorphism (SNP) 
in transmembrane 6 superfamily member 2 (TM6SF2), located on chromosome 19, was 
associated with hepatic triglyceride content (HTGC) as measured by proton magnetic 
 36 
resonance spectroscopy (1H-MRS) (100). This missense variant (rs58542926 C>T) replaces 
glutamate with lysine, and was found associated with liver fat content, reduced plasma lipid 
levels and increased levels of circulating liver enzymes. Besides, it was shown to be related 
to advanced fibrosis and cirrhosis (101) and its protein is required to mobilize lipids for 
VLDL assembly. Further, carriers of this risk variant appear to be protected against 
cardiovascular disease, but are more susceptible to develop NASH (102). This effect was 
independent of PNPLA3 rs738409 effect, obesity and insulin resistance or alcohol intake.  
The identification of novel genetic risk variants and the introduction of predictive 
models could be useful tools for the clinical management and stratification of patients at risk. 
Next-generation approaches could soon develop more precise genetic biomarkers, which 
should be cost-effective technologies applicable to clinical practice (figure 6). 
 
 
Figure 6. Most relevant genetic and epigenetic studies carried out for different NAFLD 
features. 
 
Hence, there is a need for novel molecular markers that could help in early and 
moderate disease stages. Knowledge of epigenetics and heritable events not caused by 
changes in DNA sequence have contributed to the development of broad spectra of diseases 
has been a revolution in the past few years. More recently, evidence is accumulating to reveal 
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the fundamental role of epigenetics in NAFLD pathogenesis and NASH genesis (103). 
Among the main epigenetic mechanisms, microRNAs have received growing attention.  
MicroRNAs or miRNAs are highly conserved, naturally occurring, single-stranded, 
non-coding RNA molecules that are less than 25 nucleotides long. They modulate several 
biological situations by regulating gene expression at post-transcriptional levels. 
Additionally, they are usually deregulated under pathological conditions, around 30% of 
mRNA expression, and exert their function by pairing with complementary sequences of 
target mRNA. Since they are present in many biofluids, they offer a great potential as non-
invasive biomarkers. Circulating miRNAs are highly stable in serum or plasma samples, free 
or packaged for protection against RNAse activity. Latest advances in molecular biology 
have enhanced our knowledge about genotype-phenotype relationships, and several miRNAs 
have been used as biomarkers to detect NAFLD injuries. However, the main difficulties 
remain in standardization procedures and high cost, which is necessary before their 
translation into clinic (table 3). 
 
Table 3. Summary of non-invasive methods for main NAFLD features 
STEATOSIS NASH FIBROSIS 
CT 
CAP 
MRS 
SteatoTest® 
PDFF-MRI 
13C-MRS 
CK-18 
FGF21 
OWL-Liver® 
NashTest® 
Genetics 
Epigenetics 
NFS 
FibroTest® 
FibroMeter® 
Transient elastography 
Forns, APRI, FIB-4 
MRE 
ARFI 
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NAFLD encompasses two distinct entities, a benign simple steatosis and its 
progressive form, NASH, which can lead to severe outcomes. Steatohepatitis and advanced 
fibrosis have been associated with an increased mortality rate between 5 and 10 times 
respectively. Indeed, NASH can evolve towards cirrhosis and hepatocellular carcinoma. 
Nevertheless, it is possible to stop or slow disease progression by life-style intervention and 
pharmacological treatment. Currently, new insights into its progression, particularly 
concerning identifying the initiating mechanisms and patients at risk, as well as developing 
innovative diagnostic methods adapted for large scale screening evaluation. In order to define 
prognosis and appropriate therapeutic management, a critical issue is the differentiation of 
NASH from simple steatosis that remains a major clinical challenge. 
Based upon the knowledge that accurate diagnosis, effective treatment and operative 
tools to monitor disease response are the three pillars essential in support of medical practice; 
thus, the development of an accurate, reliable, non-invasive and cost-effective tool is 
mandatory. 
Thus, considering that both liver fibrosis and NASH generate several morphological 
changes in tissue structures that could be determined by optical analysis of magnetic 
resonance images, the relationship between this analysis and tissue alteration due to the 
disease could be patterned, to diagnose the disease.  
Genetic markers are heritated stably and pose a substantial predictive capacity not 
influenced by external agents. Finally, taking into account circulating microRNAs are highly 
stable in serum or plasma samples, and currently there is a wide range or miRNAs profile 
technologies based on sequence specificity, both small non-codifying molecules and genetic 
variants could constitute powerful non-invasive diagnostic tools.  
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In the current study, the main aim was to develop, standardise and validate imaging 
biomarkers defined by optical processing methods applied to conventional non-enhanced 
contrast magnetic resonance images to predict, using non-invasive tools, steatohepatitis and 
fibrosis stages in NAFLD patients.  
 
The secondary objective was to identify, select and compare those emergent imaging 
biomarkers with currently available biochemical markers that will be transformative for the 
clinical management of patients. 
 
Finally, the last aim was to identify novel genetic and epigenetic biomarkers that 
could be used as non-invasive tools for NASH and significant liver fibrosis detection.  
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This project was initially designed considering the background evidence, need for the 
study, epidemiology of the underlying disorder and the magnitude of expected benefits over 
currently available diagnostic options. Number, location and centers involved were decided at 
the beginning of the study; however, three more Centres were incorporated during last year 
and a half to increase sample size and validate this approach. 
Qualification process development included proof of concept, proof of mechanism, 
biomarkers acquisition and analysis, proof of principle and proof of efficacy and 
effectiveness.  
The main aim, discrimination of NASH and significant fibrosis, did not change over 
time. After the consecution of this objective, it was integrated the supplementary non-
invasive approaches to performing the comparative analysis. 
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5.1 Patients, inclusion and exclusion criteria and ethical aspects of the 
research 
Individuals were recruited from several Hepatology Units, and all patients provided 
informed consent for liver biopsy, MRI study and blood extraction (See annexed material).  
They must fulfil, at least, two of the following three inclusion criteria: a) adults (>18 years of 
age) who showed diffuse hyperechogenic liver on ultrasonography; b) impairment in 
biochemical liver profile, stated as sustained ALT or AST above ULN for at least 6 months; 
c) metabolic syndrome following ATPIII criteria (104). Exclusion criteria were: significant 
alcohol intake (>30 g/day in men and >20 g/day in women), recreational drugs abuse, 
pregnancy; parenteral nutrition, evidence of viral or autoimmune hepatitis, HIV, drug-
induced fatty liver or other metabolic liver diseases (such as hemochromatosis or Wilson’s 
disease), together with pregnancy and parenteral nutrition. 
The study protocol conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki, as revised in 1983. The Institutional Review Board Committee from each 
participating hospital approved the study protocol (Virgen Macarena-Virgen del Rocío 
University Hospitals, Valme University Hospital, Città della Salute e della Scienza di Torino 
Hospital, Marqués de Valdecilla University Hospital, Virgen de la Victoria University 
Hospital, Tajo University Hospital and Puerta de Hierro University Hospital) (see annexed 
material). Study procedures followed were in agreement with the ethical standards of the 
responsible committee on human experimentation, and were approved by the human research 
ethics committee from each Center. 
All patients underwent a screening visit including medical history, physical 
examination, and laboratory tests. An electronic case report form (CRF) was employed to 
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warranty integrity and quality of data, and all aspects related to patients´ privacy were 
considered. All data were coded, and the database was anonymized. 
 
5. 2 Clinical, anthropometric and biochemical measurements 
 
Patients underwent a complete medical history, physical examination, liver biopsy and 
imaging study. Clinical and laboratory data were collected at the same time of liver biopsy. 
Basic anthropometric data included body mass index (BMI), calculated as the weight in 
kilograms divided by the square of height in meters, and abdominal perimeter. Comorbidities 
included the presence of type 2 diabetes mellitus, arterial hypertension, and dyslipidaemia, 
and concomitant treatments at the time of biopsy were recorded.  
An overnight (12h) fasting blood sample was taken at the same time of liver biopsy 
for routine biochemical analyses that were performed at the central laboratory of each 
University Hospital, to rule out occult diseases. Routine blood biochemistry and haematology 
analyses included the transaminases (ALT, AST), γGT, alkaline phosphatase, total 
cholesterol, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol 
(LDL-c), total bilirubin, albumin, triglycerides and viral serology for hepatitis B and C 
viruses. Serum insulin levels were measured by electrochemiluminescence immunoassay, 
using an Elecsys 1010/2010 autoanalyzer (Elecsys MODULAR ANALYTICS E170; Roche, 
Basil, Switzerland).  
Samples were centrifuged 10 minutes at 3,500 revolutions per minute (rpm) right after 
obtained, alicuoted and immediately stored at -80ºC until assayed. CK-18 was measured 
using a human enzyme-linked immunosorbent assay (ELISA) kit (Abnova, Walnut, CA, 
USA). Circulating FGF21 levels were measured in 50uL using a human commercial ELISA 
assay (Biovendor, Karasek, Czech Republic) according to the manufacturer´s instructions. 
 51 
Inter-assay and intra-assay coefficients of variation were 3.3% and 2.0% respectively. 
Minimal detectable concentration was 7 pg/mL. 
Finally, NAFLD Fibrosis Score (77) and Sydney Index (105) were calculated as 
previously reported and transient elastography was measured using FibroScan (Echosens, 
France) in fasting patients.  
 
5.3 Histological staging and grading 
 
Percutaneous liver biopsies were performed under local anaesthesia and ultrasound 
guidance. Liver specimens were obtained, after an overnight fast, by “tru-cut” needle (sample 
length/diameter = 20/1.2 mm) using a biopsy gun. At least one sample per patient was 
obtained. Lengths of liver specimens were recorded, as were the number of portal tracts. The 
sample was then assessed as being useful or not for histological diagnosis and fibrosis 
staging; samples of <10 mm length or <15 portal tracts were excluded. Biopsies were 
processed using standard procedures, formalin-fixed and paraffin-embedded and a fraction 
was immediately shock-frozen and stored at -80ºC. Any adverse events from liver biopsy 
were reported. 
A single pathologist, who was blinded with respect to provenance of the samples and 
unaware of clinical data, assessed the samples using haematoxylin-eosin, reticulin and 
Masson´s trichrome stains to determine the grading and staging assignments according to 
Kleiner et al (figure 7). This scoring system comprises four semi-quantitative features: 
steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis. Steatohepatitis 
presence was not inferred from the NAS but, instead, was diagnosed taking into account 
patterns of histological distribution of lesions focusing on inflammatory activity and 
ballooning. Kleiner NAFLD Activity Score (NAS Score) and fibrosis stage were also 
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calculated. NAS Score provides an overall score that comprises the degree of steatosis (score 
0-3), lobular inflammation (score 0-3) and hepatocyte ballooning (score 0-2).  
Hepatic steatosis was quantified as the percentage of hepatocytes containing fat 
droplets, graded on a scale of 0-3 through subjective visual estimation of cells containing fat 
vacuoles. Steatosis grades were broadly categorised for severity: grade 0 or normal (up to 5% 
of hepatocytes affected); grade 1 or mild (5-33% of cells affected); grade 2 or moderate (33-
66% showing steatosis); grade 3 or severe (>66% of hepatocytes showed fat storage).  
Lobular inflammation was assessed as: grade 0 (non-inflammation); grade 1 (<2 
foci/x200 field); grade 2 (2-4 foci/x200 field); grade 3 (>4 foci/x200 field). Ballooning was 
evaluated as: stage 0 (none); stage 1 (a few balloon cells); stage 2 (many cells or prominent 
ballooning). Fibrosis staging was based on a 5-level scale: F0=absence; F1=perisinusoidal or 
periportal; F2=perisinusoidal and portal/periportal; F3=bridging fibrosis; F4=cirrhosis.  
A further 2-level scale of fibrosis was applied: mild (F0-F1) and significant (F2-F3-F4) 
fibrosis.  
 
Figure 7. Histological findings in NAFLD patients. 
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5.4 Imaging biomarkers 
5.4.1 Study design and patients 
This was a cross-sectional and multi-centred study that included 126 well-
characterised biopsy-proven NAFLD patients who were recruited between June 2009 and 
June 2013. Estimation cohort was enrolled from June 2009 to September 2010, and validation 
set from January 2010 to June 2013. Clinical data were collected at the time of liver biopsy 
using a particular case record form, together with blood samples for biochemical analyses. 
The study sample was composed of all patients who fulfilled the inclusion criteria and 
were not disqualified by one or more of the exclusion criteria. Untreated and histologically 
confirmed NAFLD patients were recruited as part of the FLIP (Fatty Liver: Inhibition of 
Progression; www.flip-fp7.eu) project. The Fatty Liver Inhibition of Progression (FLIP) 
Consortium was formed in response to the FP7 call (figure 8). The aim of the FLIP project is 
to understand and prevent the progression of liver disease in NAFLD. The FLIP project is 
supported by the European Commission through the Seventh Framework Programme for 
Research and Development, and has been running since January 1st, 2010 (duration 36 
months).  Consortium Leader was Vlad Ratziu, and Prof. Romero-Gómez leaded work 
package specifically dedicated to non-invasive and innovative diagnostic and prognostic 
biomarkers development. 
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Figure 8. FLIP main outcomes and deliverables.  
Patients enrolled in the study were classified according to sex, age, fibrosis stage and 
presence/absence of steatohepatitis.  
5.4.2 Magnetic resonance image acquisition 
MR studies were conducted at the six University Hospitals using General Electric 
(Milwaukee, CT, USA) or Philips (Best, NL.) 1.5-Tesla whole-body systems within a period 
of six months from liver biopsy. Patients were examined in the supine position using a 
standard torso coil centred over the liver. No contrast medium was used, and the patient was 
encouraged to individual breath-holding capacity by the technologist. MRIs were sent to the 
Referral Centre for processing in standard DICOM format. The images were processed and 
interpreted by two experienced engineers independently and, finally, a consensus was 
achieved. Both engineers were blinded to clinical and histopathological data. The entire liver 
was imaged, and 6 sections were selected covering the whole organ.  
MR protocols for this study were performed in axial plane: SSFSE-T2 (Single Shot 
Fast Spin Echo T2-weighted), FAST-STIR (Fast Short inversion Time Inversion Recovery), 
inPHASE-outPHASE (in and out Phase) and DYNAMIC. DICOM files, the field of view 
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(FoV) and matrix sizes were configured specifically for each MR protocol; minimum and 
maximum window values were calculated so that each slice could be converted into a 
numerical matrix of pixels within the particular window range (table 4). 
Table 4. Instructions to patients, preparation for imaging procedure, and imaging 
parameters recorded 
 
INSTRUCTIONS -­‐ Arms up if possible -­‐ Breath hold must be consistent -­‐ Supine position -­‐ Contrast: none 
 
 
 
Imaging parameters 
Sequence name 
SSFSE-T2 FAST-STIR In and out of 
PHASE 
DYNAMIC 
Scan plane Axial Axial Axial Axial 
Imaging options Breath hold Breath hold Breath hold Breath hold 
Time (sec) 29.76 +10.05 340.98 + 104.10 38.10 + 6.66 35.44 + 
90.33 
FOV (mm) 450 400 410 375 
Matrix size (px) 512x512 448x448 432x432 192x192 
 
 
5.4.3 MR imaging processing to define NASHMRI and FibroMRI imaging 
biomarkers 
5.4.3.1 Development and standardisation of imaging biomarkers 
Thirty-nine patients were consecutively included in the estimation cohort; 20 (51%) had 
steatohepatitis, and 19 (49%) had significant fibrosis. The contour of the liver parenchyma is 
manually drawn in each slice. Each MR image is further divided according to a square grid 
that defines the set of samples (squares) to be processed. The spacing of the grid is chosen so 
that each sample square (from 10x10 pixels to 23x23 pixels, depending on image resolution 
and slice thickness) corresponds to an optimal volume of liver biopsy. Each sample is further 
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analysed to exclude those containing artefacts, such as vessels or biliary ducts. Also, those 
samples with >30% of its pixels outside the segmented area are discarded. Only those grid 
squares comprising liver parenchyma are analysed.  
MR image features, segmentation algorithms, and implementation codes were developed 
in MATLAB (Matrix Laboratory, MathWorks, Natick, MA, USA) programming language. 
The software tool imports DICOM MR files and parses them, extracting all relevant 
information needed, including patient’s clinical and demographic data from the MR protocol.  
The image-processing algorithms comprise the following steps. First, the whole set of 
MR slices are presented to the user. The user, preferably those that contain the major liver 
section, must choose up to 6 consecutive slices (figure 9). 
 
Figure 9. MRI acquisition and selection of six MR images containing liver 
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In each selected image, the user outlines the liver boundary (figure 10).  
 
Figure 10. Presentation of selected slice and manual outlining of liver boundaries. 
When the parenchyma is segmented, a square grid is automatically over-layered. Six 
slices and fifteen samples per slice are obtained, so around one hundred of valid samples per 
patient and protocol are extracted. To achieve a sample size (of each square) equivalent to a 
volume of 15 to 24 mm3 of tissue, the quantity of pixels of each sample is computed using the 
FoV, the number of rows and columns of the image matrix and the slice thickness. Therefore, 
the final amount of samples processed varies for different MR sequences, but this method 
increases diagnostic accuracy, due to liver biopsy analyses 1/50,000 of the whole liver, and 
using this approach this number is reduced to 1/25.  
The software automatically discards those samples with >30% of the surface outside 
the segmentation line i.e. with a minimum of 70% pixels exhibiting liver parenchyma. The 
user must also reject samples that do not represent homogeneous liver tissue (i.e. those pixels 
containing vessels, ducts or other elements) (figure 11).  
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Figure 11. Segmentation, overlapping and valid sample selection process of the square grid. 
A total of 84 different mathematical image parameters or "estimators" are computed 
from each sample. The nature of these parameters ranges from simple statistical descriptors 
such as mean and standard deviation to advanced image processing properties such as energy 
and entropy, geometrical properties like mean surface curvature, and spectral characteristics. 
All calculated parameters for each sample (patient and protocol), are related to clinical 
features (biochemical parameters and histological scores) of NASH and fibrosis using logistic 
regression to determine the optimal combination of protocols and parameters.  
5.4.3.2 Validation of imaging biomarkers 
The imaging biomarkers that were developed were validated in a cohort of 87 
patients. No differences were observed concerning age, gender, steatosis degree, 
steatohepatitis or fibrosis distribution between the estimation and the validation cohorts. The 
average time consumed in MR studies was around 11±3 minutes. 
 
5.4.4 Comparison with biochemical biomarkers and transient elastography 
 NASH-MRI was compared with serum CK-18 levels. The FibroMRI was compared 
with Sydney Index, the NAFLD Fibrosis Score, and the transient elastography.  
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5.5 Genetic and epigenetic biomarkers 
5.5.1 Patients and study design 
This was a multicentre cross-sectional study including 225 biopsy-proven NAFLD 
patients showing different stages of the disease. Significant fibrosis was diagnosed in 22.2% 
(50/225) of the overall cohort, while NASH was present in 31.1% (52/167).  
 
5.5.2 DNA isolation, quantification and single-nucleotide polymorphisms 
genotyping 
Two-hundred-and-twenty-five biopsy-proven NAFLD patients were included (see 
table below). DNA was automatically isolated from 400 µL of whole blood by Magnapure® 
Compact equipment (Roche Diagnostics) following manufacturer´s protocol. DNA 
quantification was performed by NanoDrop™ 2000® (Wilmington, USA) to avoid chemical 
interferences in the process. FGF21 rs838133, PNPLA3 rs738409, and TM6SF2 rs58542926 
variants were determined by allelic discrimination by predesigned Taqman assay (Applied 
Biosystems, Foster City, CA, EEUU) on DNA isolated. All SNPs were confirmed to be in 
Hardy-Weinberg equilibrium (figure 12).  
 
 
Figure 12. SNPs depiction.  
 60 
5.5.3 Evaluation of FGF21 liver expression and peripheral mononuclear blood cells 
Total RNA was isolated from 20 frozen human liver tissues using miRvana miRNA 
Isolation kit (Ambion, Life Technologies, USA) and mRNA levels were evaluated by 
quantitative real-time polymerase chain reactions (qRT-PCR). Ten patients presented NASH 
in liver biopsy and other ten just simple steatosis. Quantification of total RNA samples was 
determined by spectrophotometry using Qubit 2.0 (Invitrogen, Life Technologies, USA). 
RNA Integrity number (RIN) was measured by electrophoresis (Agilent Technologies, Inc.) 
to ensure the quality of samples. Cases presenting RIN<5 were not suitable for the analysis. 
qRT-PCR reactions were carried out in triplicate (SensiFAST™ SYBR Lo-ROX One-Step Kit 
(Bioline, EEUU) in Eco™ Real-Time PCR System (illumina®, EEUU). RNA normalization 
was performed by amplification of RNA 18S as an endogenous control. The 2-ΔΔCT method 
was used for the analysis of the relative gene expression (106), and results were expressed as 
fold change. 
Besides, total RNA from peripheral blood mononuclear cells (PBMC) was extracted 
from 30 patients (15 NASH and 15 simple steatosis) using TriZol Reagent (Invitrogen, 
Carlsbad, CA) and qRT-PCR was performed following the same protocol as described above. 
5.5.4 Liver microRNAs isolation and quantification 
Small RNA fraction, containing microRNAs profile, was isolated from 20 liver 
samples (10 presenting NASH and 10 displaying simple steatosis) by using miRvanaTM 
miRNA Isolation kit (Ambion, Life Technologies, USA) (figure 13). This kit employs an 
organic extraction followed by immobilization of RNA on glass-fiber filters to purify either 
total RNA, or RNA enriched for small species, from cells or tissue samples. High yields of 
ultra-pure, high quality, small RNA molecules can be prepared in about 30 min. The sample 
is first lysed in a denaturing lysis solution, which stabilizes RNA and inactivates RNases. The 
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lysate is then extracted once with Acid-Phenol: Chloroform, which removes most of the other 
cellular components, leaving a semi-pure RNA sample. This is further purified over a glass-
fiber filter by one of two procedures to yield either total RNA or a size fraction enriched in 
miRNAs. The glass-fiber filter method uses solutions formulated specifically for microRNA 
retention to avoid the loss of small RNAs that is typically seen with glass-fiber filter methods. 
 
Figure 13. MiRvanaTM isolation. 
After assessment of the quality of samples (Agilent 2000 Bioanalyzer (Agilent 
Technologies, Inc.), a screening of microRNAs with potential impact on the disease was 
performed. 96-wells miScript miRNA PCR Array Human Liver (QIAgen, Hilden, Germany) 
was employed, for SYBR® Green-based, real-time PCR profiling of miRNAs (figure 14). 
This methodology uses mature miRNA-specific forward primers (miScript Primer Assays) 
that have been arrayed in biologically relevant pathway-focused, disease-focused, or whole 
miRNome panels.  
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Figure 14. Liver samples methodology  
Pooled cDNA at equal concentration were prepared according to two different 
conditions (NASH and SS) using the miScript II RT Kit and used as a template in real-time 
PCR with a miScript miRNA PCR Array and the miScript SYBR Green PCR Kit. Wells 1 to 
84 each contain a miScript Primer Assay disease-related. Wells 85 and 86 contain replicate C. 
elegansmiR-39 miScript Primer Assays that can be used as an alternative normalizer for array 
data. Wells 87 to 92 each include an assay for a different snoRNA/snRNA that can be utilized 
as a normalization control for the array data (figure 15). 
 
Figure 15. QIAgen predesigned array for candidates’ evaluation. 
After analysing the array layout, two candidates were identified and independently 
validated in liver samples. Thus, qRT-PCR reactions were carried out in triplicate using 
SNORD96A as endogenous control and hsa-miR-200b and hsa-miR-224 (QIAgen, Hilden, 
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Germany). cDNA synthesis was prepared from human liver tissues by using miScript reverse 
transcription kit (QIAgen, Hilden, Germany) and qRT-PCR reactions were performed by 
miScript PCR kit. 
5.5.5 Serum microRNAs isolation, quantification, and analysis 
Further, to validate the potential of these microRNAs as surrogate biomarkers of the 
disease, small RNAs were isolated from 40 plasma samples, 20 from NASH patients and 20 
with SS by using the miRNeasy mini kit (QIAgen, Hilden, Germany) (figure 16). This kit 
combines phenol/guanidine-based lysis of samples and silica-membrane–based purification 
of total RNA. QIAzol Lysis Reagent is a monophasic solution of phenol and guanidine 
thiocyanate, designed to facilitate lysis, to denature protein complexes and RNases, and also 
to remove most of the residual DNA and proteins from the lysate by organic extraction. After 
addition of 200 uL of sample per patients, QIAzol, and chloroform, the lysate is separated 
into aqueous and organic phases by centrifugation. RNA partitions to the upper, aqueous 
phase, while DNA partitions to the interphase and proteins to the lower, organic phase or the 
interphase. The upper, aqueous phase is extracted, and ethanol is added to provide 
appropriate binding conditions for all RNA molecules from approximately 18 nucleotides 
upwards. The sample is then applied to the RNeasy MinElute spin column, where the total 
RNA binds to the membrane and phenol and other contaminants are efficiently washed away. 
High-quality RNA is then eluted in a small volume of RNase-free water. 
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Figure 16. MiRNeasy Serum/plasma isolation procedure.  
 
The quality of samples was further evaluated by NanoDrop™ 2000® (Wilmington, USA) to 
analyse the chemical interferences with QIAzol reagent. cDNA synthesis was prepared by 
using miScript reverse transcription kit (QIAgen, Hilden, Germany) and PCR reactions were 
carried out in triplicate by using miScript PCR kit following manufacturer´s instructions, 
using SNORD96A again as housekeeping gene.  
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5.6 Statistical analyses  
Software package SPSS 22.0 (IBM, Chicago, IL, USA) was used to record data and to 
perform the detailed statistical analysis. Graphs were generated with both SPSS and Graph 
Pad Prism 6.0 (La Jolla, California). All p-values <0.05 were considered statistically 
significant. Normally distributed data are presented as mean + standard deviation (SD) and 
median (interquartile range) for non-normal continuous variables, whereas proportions were 
used for discrete variables. 
5.6.1 Imaging biomarkers analysis 
Receiver operating characteristics (ROC) curves, which represent the trade-off 
between the true and false-positive rates, were used to differentiate the misclassified data 
between normal and disease status. The statistical method to compare the area under the 
receiver operating characteristic (AUROC) curves was based on the method of Hanley et al 
(107, 108)  
NASH and significant fibrosis (F2-F4) were dichotomised as presence or absence of 
the feature. NASHMRI and FibroMRI were the outputs of the optical analyses and were 
defined as predictive models to detect steatohepatitis and significant fibrosis. Multiple 
logistic regressions were performed to establish the final formula for NASH calculation 
(NASHMRI), and significant fibrosis (FibroMRI) presence. The sample size was intended to 
detect significant differences between histological diagnosis and NASHMRI and FibroMRI, 
using nQuery Advisor v7.0 software. Sample size of the validation cohort was 84 patients 
with a significance level (alpha) of 0.05, 1 – power (beta) of 0.20, prevalence of 
steatohepatitis of 0.5 and, under the hypothesis of AUROC curve, a difference <0.12 (i.e. 
AUROC for NASHMRI of 0.83 and for histological steatohepatitis of 0.95). 
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5.6.2 Genetic and epigenetic analysis 
Statistical analyses using t-tests or ANOVA were carried out for normal distributions, 
and U-Mann Whitney or Kruskal-Wallis tests were carried out for non-normal variables. 
Categorical variables were explored by X-squared analysis, and finally, continuous variables 
were assessed by Pearson correlation coefficient. Independent variables were showing p-
values <0.05 in univariate analysis were entered into backward Wald logistic regression 
analysis for genotyping evaluation, to escape from potentially confounding factors, to 
identify factors related to steatohepatitis and liver fibrosis. A multivariate model was 
constructed sequentially with variables entered one at the time, and a significance level of 
0.05 was used to eliminate them from the model. Odds ratios (OR) and their 95% confidence 
intervals were estimated. The method used for missing data was complete-case analysis since 
statistical packages excluded individuals with any missing value. Serum FGF21 levels were 
converted to natural logarithm to normalize data.  
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6.1 IMAGING BIOMARKERS 
6.1.1 Development and standardisation of NASHMRI to detect steatohepatitis 
One hundred and twenty-six patients were included on this analysis. Main 
characteristics of the overall cohort are summarized in table 6, and principal comparisons 
between estimation and validation cohorts in table 7. 
Estimator E3 (harmonic mean) from MRI protocol SSFSE-T2, estimator E57 (second 
order contrast) from DYNAMIC MRI protocol, and estimator E73 (weighted mean curvature) 
from MRI protocol FAST-STIR, were found to be independently associated with NASH. 
Model coefficients associated with each one of these independent variables were β1=0.079 
(OR: 1.08, 95%CI: 1.02-1.15; p=0.015) and β2=0.127 (OR: 1.14, 95%CI: 1.03-1.26; 
p=0.015). The influence of these estimators on the predictive equation to obtain the 
probability of suffering steatohepatitis was developed on estimation cohort and is given by:  
NASHMRI = 1/ 1 + e 1.654 - 0.079*E3 (SSFSE-T2) – 0.127*E57 (DYNAMIC)*E73 (FAST-STIR) 
In the estimation cohort (n=39), AUROC obtained was 0.88 (95%CI: 0.77-0.99). 
Mean NASHMRI discriminated between simple steatosis and steatohepatitis, with high 
sensitivity (Se) and specificity (Sp). The best cut-off (based on Se and Sp) to segregate 
patients according to steatohepatitis presence or absence was 0.5; patients with a NASHMRI 
score > 0.5 were considered as NASH presence (figure 17). With this threshold, Se was 87%, 
Sp 74%, positive predictive value (PPV) 80% and negative predictive value (NPV) 82%.  
In the validation cohort (n=87), NASHMRI AUROC obtained was 0.83 (95%CI: 
0.75-0.92). Using the defined threshold of 0.5 for NASHMRI prediction, the results achieved 
were: Se 87%, Sp 60%, PPV 71% and NPV 81%.  
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Table 6. Baseline characteristics of the patient population: metabolic, demographic, and 
anthropometric data.  
 
Parameter Overall cohort 
 (N=126) 
Age; years  51±12 
Male gender; % 78 (62%) 
Body mass index; kg/m2 30.6±4.8 
Waist circumference; cm 102±11 
Caucasian ethnicity; % 100 
Arterial hypertension; % 36.4 
Diabetes; % 37.5 
Cholesterol; mmol/L 8.5±10.9 
Triglycerides; mmol/L 5.9±11.7 
ALT; IU/L 73±44 
AST; IU/L 46±39 
GGT; IU/L 101±101 
Platelet count; x109 233±57 
Fasting glucose; mmol/L 5.6±3.8 
HOMA index 3.8+2.8 
Insulin; mg/dL 14.9±9.3 
Albumin; g/dL 4.3+0.4 
Sydney Index 0.31+0.31 
NFS -1.5+1.73 
Transient elastography; kPa 7.6+6.1 
CK-18; ng/ml 
Liver biopsy length; mm                                              
0.31+0.25 
17.5+3.0 
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Table 7. Baseline characteristic comparisons between cohorts 
 
Parameter Overall  
Cohort 
 (N=126) 
Estimation 
Cohort 
 (N=39) 
Validation  
Cohort 
 (N=87) 
P 
Age; years  51±12 52+11 50+13 ns 
Male gender 83 (66%) 29/39 (74%) 54 (62%) ns 
BMI; Kg/m2 30.6±4.8 29.2+4.8 31.1+5.1 ns 
Steatosis grade; %    ns 
     1 75 (60%) 21 (54%) 54 (62%) ns 
     2 31 (24%) 10 (26%) 21 (24%) ns 
     3 20 (15%) 8 (21%) 12 (14%) ns 
NASH; % 65 (51%) 21 (54%) 44 (51%) ns 
Fibrosis stage; %    ns 
F0 52 (41%) 13 (33%) 39 (44%) ns 
F1 24 (19%) 7 (18%) 17 (20%) ns 
F2 27 (21%) 9 (23%) 18 (21%) ns 
F3 16 (13%) 7 (18%) 9 (10%) ns 
F4 7 (6%) 3 (8%) 4 (5%) ns 
 
 
Figure 17. Box plot of NASHMRI according to NASH presence 
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6.2.2 Definition of FibroMRI for significant fibrosis prediction 
Estimator E22 (Pearson’s asymmetry coefficient) from MRI protocol SSFSE-T2 and 
estimators E3 (harmonic mean), E6 (mode), E31 (column’s mean of multi-oriented co-
occurrence matrix) and E75 (maximum of main curvatures) from MRI protocol DYNAMIC 
were found to be independently associated with fibrosis (table 8).  
Model coefficients associated with each of these independent variables were: 
β1=1.101 (OR: 3.01, 95%CI: 1.25-7.25; p=0.014); β2= -1.105 (OR: 0.33, 95%CI: 0.14-0.77; 
p=0.010); β3= -115.737 (OR: 0.08, 95%CI: 0.02-0.14; p=0.046); β4=0.696 (OR: 2.00, 95%CI: 
1.19-3.38; p=0.009); and β5= -0.825 (OR: 0.44, 95CI%: 0.21-0.93; p=0.030). Their 
introduction into the predictive equation defining the risk of suffering fibrosis was: 
Fibro-MRI= 1/ 1+e -4.207-1.101*E3 (DYNAMIC) + 1.105*E6 (DYNAMIC) + 115.737*E22 (SSFSET2) –0.696*E31 
(DYNAMIC) + 0.825*E75 (DYNAMIC) 
In the estimation cohort (n=39), AUROC obtained was 0.94 (95%CI: 0.87-1.00). 
FibroMRI differentiated between mild (F0-F1) and significant (F2-F3-F4) fibrosis, without 
any overlap. The best cut-off, determined by Se and Sp, to segregate patients with absence or 
presence of significant fibrosis was 0.5; those patients with a FibroMRI > 0.5 were 
considered as suffering from significant fibrosis (figure 18). With the previously defined cut-
off point of 0.5 for FibroMRI, the results obtained were: Se 81%, Sp 85%, PPV 77% and 
NPV 86%. In the validation cohort (n=87), FibroMRI AUROC for significant fibrosis was 
0.85 (95%CI: 0.77-0.93). With the defined threshold at 0.5 for FibroMRI prediction, the 
results obtained were: Se 77%, Sp 80%, PPV 67% and NPV 87%.  
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Table 8: Definition and properties of the estimators 
 
PROTOCOL ESTIMATOR NAME DEFINITION AND PROPERTIES 
SSFSE-T2 E3 Harmonic 
mean 
The harmonic mean of a set of values, in this 
case, the set of pixels of a sample, is a special 
type of media used when the average of rates 
is desired. The harmonic mean is the 
reciprocal of the arithmetic mean of the 
reciprocals 
DYNAMIC E57 Second order 
contrast 
Another texture attribute of a given sample, 
computed as a local grey level variation in the 
grey level co-occurrence matrix. It can be 
thought of as a linear dependency of grey 
levels of neighbouring pixels. If the 
neighbouring pixels are very similar in their 
grey level values then the contrast in the 
image is very low. In case of texture, the grey 
level variations show the variation of texture 
itself. High contrast values are expected for 
heavy textures and low for smooth, soft 
textures 
FAST-STIR E73 Weighted 
mean 
curvature  
Curvature is a feature used to describe image 
surface. The Weighted mean curvature is a 
value representing the mean of the curvatures 
mean at each pixel within the image sample. 
SSFSE-T2 E22 Pearson’s 
asymmetry 
coefficient 
Pearson’s asymmetry coefficient, also called 
Pearson’s first coefficient of skewness, is a 
way to figure out the skewness of a 
distribution. It tells how far the distribution 
departs from symmetry. 
DYNAMIC E6 Mode The Mode of a set of numbers, in this case the 
pixel sample values, is the value that occurs 
most often. 
DYNAMIC E31 Column’s 
mean of 
multi-
oriented co-
occurrence 
matrix 
In image processing, co-occurrence matrices 
are used to analyse the texture of an image. A 
multi-oriented matrix computes the 
magnitude and orientation of the local 
gradient vector at each pixel position, so each 
pixel carries its grey value, its gradient 
magnitude and its gradient orientation. 
DYNAMIC E75 Maximum 
of main 
curvatures 
In this case, the maximum value for all the 
primary curvatures (primary curvature from 
every pixel of the sample) is used as a surface 
attribute descriptor. 
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Number of patients suffering from advanced fibrosis and/or cirrhosis was not enough 
to define outright thresholds beyond significant fibrosis. Nevertheless, FibroMRI correlated 
with fibrosis stage (r=0.54;p<0.0001), independently of device used (General Electrics (GE) 
r=0.54;p<0.001 and Philips r=0.44;p<0.002). Finally, FibroMRI was found different 
according to the stage of fibrosis: F0 (n=36) 0.16+0.24 [95%CI 0.07-0.24]; F1 (n=16) 
0.34+0.40 [95%CI 0.12-0.55] and F>2 (n=30) 0.64+0.30 [95%CI 0.53-0.75]; p<0.0001. 
 
Figure 18. Box plot of FibroMRI according to significant fibrosis detection. 
 
6.2.3. Comparative analyses of NASHMRI and FibroMRI 
6.2.3.1 Standardisation of NASHMRI and FibroMRI across MRI systems 
NASHMRI calculated using GE scanners (n=35) showed a similar diagnostic 
accuracy when compared with NASHMRI calculated in patients who underwent MRI using 
the Philips system (n=52) i.e. AUROC=0.75 (95%CI: 0.56-0.95) vs. AUROC=0.85 (95%CI: 
0.73-0.97), respectively (p=ns). Regarding FibroMRI, evaluations performed using GE MRI 
scanners showed an AUROC of 0.80 (95%CI: 0.65-0.95) vs. AUROC of 0.84 (95%CI: 0.72-
0.96) using the Philips system (p=ns). Scores yielded by both scanners are comparable, and 
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the same thresholds for NASHMRI and FibroMRI applied to both devices (GE or Philips). 
Spearman coefficient together with diagnostic accuracy was similar for both scanners and 
end-points.  
Both machines pose the same image quality and resolution and were processed 
likewise with FibroMRI and NASHMRI without distinctions. In a subset of 9 patients, both 
studies were available (6 w/o fibrosis and 5 w/o NASH). Fibrosis was detected by both 
methods in 3/3 cases and excluded fibrosis in 5/6 cases without this condition using both 
Philips and GE devices. Besides, NASH was confirmed in 3/4 cases by both techniques and 
excluded in 4/5 cases. Further analysis including a large cohort of patients would better 
define the reproducibility of these results. 
 
6.2.3.2.Comparative analysis with non-invasive biochemical markers of 
steatohepatitis 
 NASHMRI was compared with CK-18 levels in NASH diagnosis. NASHMRI offered 
the best diagnostic accuracy with an AUROC of 0.86 (95%CI: 0.76-0.96) for steatohepatitis 
presence. This was significantly better than CK-18 levels, which showed an AUROC of 0.56 
(95%CI: 0.40-0.71; p<0.05) (Figure 1). NAS score correlated significantly with NASHMRI 
(r=0.38; p<0.001) and CK-18 levels (r=0.29; p<0.02) (figure 19) 
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Figure 19. Analysis of diagnostic accuracy for NASH detection comparing NASHMRI and 
CK-18. 
 
6.2.3.3.Comparative analysis with non-invasive biochemical markers of 
significant fibrosis 
 FibroMRI was significantly superior to NFS and Sydney Index (AUROC: 0.85; 
95%CI: 0.74-0.97 vs. AUROC: 0.76; 95%CI: 0.61-0.91 vs. AUROC: 0.69; 95%CI: 0.50-
0.87, respectively; p<0.05) in predicting significant fibrosis. Fibrosis stage correlated with 
FibroMRI (r=0.61; p<0.001), and NFS (0.52; p<0.001). Also, a significant correlation 
between NFS and FibroMRI was observed (r=0.53; p<0.001) (figure 20).  
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Figure 20. Analysis of diagnostic accuracy for significant fibrosis (≥F2) comparing 
FibroMRI, Sydney Index and NAFLD Fibrosis Score.  
Lastly, findings with FibroMRI were similar to that of transient elastography (AUROC: 0.95; 
95%CI: 0.88-1.00 vs. AUROC: 0.91; 95%CI: 0.81-1.00, respectively; p=ns) (figure 21). 
 
Figure 21. Analysis of diagnostic accuracy for significant fibrosis (≥F2) detection comparing 
Fibro-MRI and valid transient elastography measurements.  
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6.2 GENETIC AND EPIGENETIC BIOMARKERS 
6.2.1 Hepatic FGF21 expression is increased in NASH patients  
Main characteristics of this substudy cohort are summarized in table 9.  
Table 9. Main features of the group of patients analysed.  
VARIABLE Cohort (N=20) 
Age (years) 46.2+9.7 
Gender (male/female) 60%/40% 
BMI (kg/m2) 28.45+4.71 
Diabetes mellitus (%) 25% (5/20) 
Arterial hypertension (%) 20% (4/20) 
HOMA-IR 3.6+2.6 
ALT (IU/mL) 48.7+25.1 
AST (IU/mL) 34.3+17.3 
GGT (IU/mL) 120.7+122.9 
NASH (%) 50% (10/20) 
Significant fibrosis  (F2-F4) (%) 10% (2/20) 
Steatosis, presence (%) 55% (11/20) 
Ballooning degeneration, presence (%) 30% (6/20) 
 
Quantitative RT-PCR analysis showed that hepatic FGF21 expression was increased 
in individuals presenting NASH and inhibited in simple steatosis (fold change 3.45+4.0 vs. 
0.63+0.90, p=0.002) (figure 23). RNA 18S expression was observed in control samples, with 
positive amplification at cycle 10, and FGF21 expression was detected at cycle 28.  
 
Figure 23. Liver FGF21 expression 
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Further, a significant correlation was found between FGF21 mRNA levels and BMI 
(r=0.736, n=14; p=0.004), endogenous insulin levels (r=0.613, n=14; p=0.02), HOMA-IR 
(r=0.552, n=14; p=0.041) and transient elastography (r=0.687, n=10; p=0.028). PBMC were 
also analysed for FGF21 mRNA abundance, but no PCR products were detected by qRT-
PCR analysis. 
 
6.2.2 Serum FGF21 levels are increased in advanced NAFLD 
Thirty-eight patients were examined, nineteen showing NASH at liver biopsy and 
other nineteen just simple steatosis. No patient presented serum FGF21 levels below 
quantification limit. Correlation analyses were performed between serum FGF21 levels and 
several anthropometric and metabolic characteristics of patients. NASH patients showed 
increased serum FGF21 levels compared to non-NASH subjects (2.17+0.77 vs. 1.55+0.79; 
p=0.025). Moreover, patients suffering from hepatocellular ballooning showed higher levels 
of FGF21 than patients without it (2.30+0.71 vs. 1.69+0.76, p=0.045). Finally, FGF21 levels 
were also significantly correlated with NAS Score (r=0.364, n=37, p=0.027) (figures 24 and 
25).  
  
Figures 24 and 25. FGF21 levels according to NASH and hepatocellular ballooning. 
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Furthermore, consistently with FGF21 mRNA expression, protein production was 
increased in patients with advanced fibrosis (F3-F4) vs. mild fibrosis (F0-F1-F2) (2.18+0.77 
vs. 1.75+0.79; p=ns) but not statistically significant.  
6.2.3 Bearing GG genotype from PNPLA3 rs738409 confers susceptibility to NASH 
development 
First, two hundred and twenty five biopsy-proven NAFLD patients, mean age 47 
years and almost 60% female composed this cohort. Main clinical and epidemiological 
characteristics of the overall cohort are provided in Table 10. Up to 31% of patients showed 
NASH in liver biopsy and more than 22% significant fibrosis stages (F2-F4) (table 10). 
 
Table 10. Baseline characteristics of the patient population: metabolic, demographic, and 
anthropometric data.  
 
VARIABLE Overall cohort (N=225) 
Age (years) 47.4+13.2 
Gender (male/female) 42%/58% 
BMI (kg/m2) 32.2+9.1 
Diabetes mellitus (%) 16.4% (37/225) 
Arterial hypertension (%) 24% (54/225) 
HOMA-IR 3.5+4.6 
Glucose (mg/dL) 100.45+28.6 
Insulin (microUI/mL) 13.14+12.77 
ALT (IU/mL) 43.3+35.6 
AST (IU/mL) 32.2+27.1 
GGT (IU/mL) 72.1+101.5 
Alkaline phosphatase (IU/mL) 77.7+31.4 
Total cholesterol (mg/dL) 197.7+41.8 
HDL-c (mg/dL) 49.9+17.5 
LDL-c (mg/dL) 123.5+36.6 
Triglycerides (mg/dL) 139.3+82.3 
NASH (%) 31.1% (52/167) 
Significant fibrosis  (F2-F4) (%) 22.2% (50/225) 
Advanced fibrosis (F3-F4) (%) 10.7% (24/225) 
FGF21 rs838133 variant, AA genotype (%) 20.9% (47/225) 
FGF21 rs838133 variant, AG genotype (%) 47.1% (106/225) 
FGF21 rs838133 variant, A allele (%) 68% (153/225) 
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In univariate analysis, gender, BMI higher than 25 kg/m2, diabetes mellitus type 2, 
AST, ALT glucose, insulin, HOMA-IR, triglycerides and GG genotype from PNPLA3 were 
found statistically associated with NASH.  
 
Further, in multivariate analysis, gender [OR 2.74 (95% CI 1.18-6.93), p=0.019], 
HOMA-IR [OR 1.526 (95% CI 1.25-1.85), p=0.000] and carrying GG genotype of PNPLA3 
[OR 3.020 [95% CI 1.17-7.73], p=0.021] were found as variables independently associated 
with NASH (table 11). 
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Table 11. Univariate and multivariate analyses according to NASH (N=200).  
 
 
 
Variable 
 
Univariate analysis 
 
 
Multivariate analysis 
 
 
Simple 
Steatosis 
 (n=137) 
 
NASH 
 (n=63) 
 
p- 
value 
 
OR [95%CI] 
 
p-
value 
Gender distribution  
 (Males vs females, %) 
 
23.1 % 
 
 
41.3 % 
 
0.006 
OR 2.74  
[95% CI 1.18-
6.93] 
0.019 
 
BMI>25 kg/m2 
 
 
11.8 % 
 
33.1 % 
 
 
0.014 
 
 
 
 
Age (years) 46.3 49.9 0.098   
T2DM (diabetic vs non-
diabetic) 
23.9% 62.9% 0.000   
AST (IU/mL) 27.4 45.9 0.000   
ALT (IU/mL) 34.2 70.1 0.000   
GGT (IU/mL) 64.4 105.5 0.057   
Glucose (mg/dL) 95.6 110.8 0.001   
Insulin (mg/dL) 9.8 21.4 0.000   
HOMA-IR 2.4 6.3 0.001 OR 1.53  
[95% CI 1.25-
1.85] 
0.000 
Triglycerides (mg/dL) 122.4 159.3 0.012   
Total cholesterol (mg/dL) 199.51 199.51 0.988   
LDL-cholesterol (mg/dL) 117.4 129.7 0.179   
HDL-cholesterol (mg/dL) 53.8 46.0 0.517   
Total bilirubin 0.58  0.64 0.517   
Alkaline phosphatase 
(IU/mL) 
76.9 80.7 0.470   
Albumin (mg/dL) 4193 4253 0.581   
Platelet count (x109) 241.5 223.3 0.113   
Haemoglobin (g/dL) 14.22 14.12 0.798   
Cholinesterase 11462.2 9655.8 0.565   
HTA  29.5% 35.2% 0.443   
FGF21 (GA/AA vs GG) 22.6 %;  26.9 % 0.545   
PNPLA3 (GG vs CG/CC) 24.5 %  51.4 % 0.002 OR 3.02  
[95% CI 1.17-
7.73] 
0.021 
TM6SF2 (CT/TT vs CC) 29.9% 32.0 % 0.835   
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Combining those parameters, AUROC obtained for NASH prediction was AUROC: 0.833 
[95% CI 0.767-0.900]; p=0.000 (figure 26). 
 
 
Figure 26. AUROC for NASH prediction 
6.2.4 Carrying A-allele from FGF21 rs838133 confers susceptibility to significant 
fibrosis 
In univariate analysis, FGF21 rs838133 A-allele (AA/AG 27.5% (42/153) vs. GG 
11.1% (8/72); p=0.006) was determined as a risk factor for significant fibrosis (F2-F3-F4).  
PNPLA3 gene was also found associated with significant fibrosis (GG 32.6% (15/46) vs 
GC/CC 20.1% (36/179); p=0.040). Further variables associated with significant fibrosis were 
male gender, age at liver biopsy, BMI>25 kg/m2, type 2 diabetes mellitus, AST, ALT, GGT, 
insulin, glucose, HOMA-IR, triglycerides, and platelets. 
Besides, in multivariate analysis, variables independently associated with significant 
fibrosis were: A-allele of FGF21 rs838133 [OR 3.91 (95% CI 1.09-14.06); p=0.006]; age 
[OR 1.07 (95% CI 1.03-1.11); p=0.001]; type 2 diabetes mellitus [OR 4.08 (95% CI 1.51-
10.97); p=0.005] and ALT [OR 1.03 (95% CI 1.01-1.04); p=0.000] (table 12). 
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Table 12. Univariate and multivariate analyses according to significant fibrosis stages 
(N=225).  
 
 
 
Variable 
 
Univariate analysis 
 
 
Multivariate analysis 
 
 
Mild 
fibrosis 
(F0-F1) 
 (n=175) 
 
Significant 
fibrosis  
 (F2-F3-F4) 
 (n=50) 
 
p- 
value 
 
OR [95%CI] 
 
p-
value 
Gender distribution  
 (Males vs females, %) 
 
19.1 % 
 
 
30.0 % 
 
0.040 
  
 
BMI>25 kg/m2 
 
 
4.4 % 
 
25.3 % 
 
 
0.002 
 
 
 
 
Age (years) 45.9 52.1 0.002 OR 1.07  
[95% CI 1.03-
1.11] 
0.001 
T2DM (diabetic vs non-
diabetic) 
15.8% 46.8% 0.000 OR 4.08  
[95% CI 1.51-
10.97] 
0.005 
AST (IU/mL) 27.6 47.7 0.000   
ALT (IU/mL) 36.3 67.5 0.000 OR 1.03  
[95% CI 1.01-
1.04] 
0.000 
GGT (IU/mL) 67.1 108.2 0.054   
Glucose (mg/dL) 95.2 118.1 0.001   
Insulin (mg/dL) 10.3 23.6 0.000   
HOMA-IR 2.4 7.1 0.000   
Triglycerides (mg/dL) 122.4 159.3 0.012   
Total cholesterol (mg/dL) 196.6 201.9 0.449   
LDL-cholesterol (mg/dL) 113.2 129.3 0.179   
HDL-cholesterol (mg/dL) 50.3 48.6 0.539   
Total bilirubin 0.60  0.61 0.922   
Alkaline phosphatase 
(IU/mL) 
76.6 87.7 0.300   
Albumin (mg/dL) 4188.0 4349.2 0.060   
Platelet count (x109) 243.2 213.9 0.006   
Haemoglobin (g/dL) 14.1 14.3 0.564   
Cholinesterase 11462.2 9655.8 0.565   
HTA  19.6% 28.4% 0.126   
FGF21 (AA vs AG/GG) 11.1 %;  27.5 % 0.006 OR 3.91  
[95% CI 1.09-
14.06] 
0.037 
PNPLA3 (GG vs CG/CC) 20.1 %  32.6 % 0.040   
TM6SF2 (CT/TT vs CC) 20.7 % 29.0 % p=0.295   
 
Further, AUROC for significant fibrosis prediction was calculated, reaching 0.89 
[95% CI 0.85-0.95] (figure 27). 
 
 
Figure 27. AUROC obtained for significant fibrosis prediction. 
 
Lastly, formulas employed to obtain those AUROCs for both NASH and significant 
fibrosis prediction were the following: 
 
NASH= 1/ 1+e (-3.083-1.101*GENDER) + 1.105*GG GENOTYPE PNPLA3 + 0.423*HOMA-IR)  
 
Significant fibrosis= 1/ 1+e (-5.480-0.031*AGE + 1.587*DM2 + 0.024*ALT –1.325*A-ALLELE FGF21)  
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6.2.5 Identification of target microRNAs: miR-200b-3p and miR-224-5p 
Two candidates (miR-200b-3p and miR-224-5p) were identified after obtaining 
the results of the predesigned array. In this pooled analysis, miR-200b-3p was found 
2.8-fold overexpressed in NASH patients vs. SS, as well as miR-224 reached 3.09-fold 
(figure 28). 
 
Figure 28. Target microRNAs findings in pool of NASH vs. SS  
6.2.6 Both liver miR-200b and miR-224 are induced in NASH, steatosis and 
ballooning. 
Both liver miR-200b and miR-224 expression were found upregulated in NASH 
vs SS patients [2.60+1.57 vs 0.72+0.62, p=0.0016 and 2.51+2.06 vs 0.34+0.13, 
p=0.0005 respectively] (figures 29 and 30).  
  
Figures 29 and 30. Liver miR-200b and liver miR-224 according to NASH. 
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Besides, both miR-200b and miR-224 were associated with steatosis presence in 
liver biopsy [2.40+1.60 vs 0.71+0.62, p=0.009 and 2.23+2.12 vs 0.49+0.32, p=0.014] 
(figures 31 and 32). 
 
 
Figures 31 and 32. MiRNAs liver expression according to presence or absence of 
steatosis. 
 
Further, both miRNAs were found associated with ballooning degeneration 
[2.79+1.59 vs 1.11+1.18, p=0.027 and 2.94+2.57 vs 0.77+0.84, p=0.048] (figures 33 
and 34). 
    
Figures 33 and 34. MiRNAs liver expression according to ballooning. 
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Finally, liver miR-200b was found associated with age [r=0.708, p=0.001, 
n=17], HOMA-IR [r=0.567, p=0.028, n=15] and BMI [r=0.647, p=0.005, n=17], as well 
as liver miR-224 expression was associated with age [r=0.582, p=0.009, n=19], HOMA-
IR [r=0.614, p=0.011, n=19] and BMI [r=0.612, p=0.009, n=19]. 
6.2.7 Plasma miR-200b and miR-224 are induced in NASH but not in 
significant fibrosis, steatosis or ballooning 
 
Forty NAFLD biopsy-proven NAFLD patients, mean age around 50 years old, 
60% male and 5% with NASH composed this substudy (table 13). 
Table 13. Main features of the group of patients analysed 
VARIABLE Cohort (N=40) 
Age (years) 49.7+10.1 
Gender (male/female) 60%/40% 
BMI (kg/m2) 31.40+5.31 
Diabetes mellitus (%) 37.5%  
Arterial hypertension (%) 25%  
HOMA-IR 5.5+2.1 
ALT (IU/mL) 52.4+32.4 
AST (IU/mL) 37.6+23.4 
GGT (IU/mL) 78.9+102.3 
NASH (%) 50%  
Significant fibrosis  (F2-F4) (%) 30% 
Steatosis, presence (%) 75% 
Ballooning degeneration, presence (%) 26% 
 
In plasma of patients with NASH miR-200b was found increased vs simple 
steatosis individuals (fold change 2.00+1.30 vs 0.96+1.09; p=0.03) (figure 35), but not 
with significant fibrosis stages (p=0.6), steatosis presence (p=0.49) or ballooning 
(p=0.38).  
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Figure 35. MiR-200b plasma expression according to NASH 
 
Further, miR-224 was found upregulated in NASH vs SS (fold change 1.60+1.52 
vs 0.26+0.32; p=0.002) (figure 36), but again not in significant fibrosis patients 
(p=0.20) or steatosis presence (p=0.37). It was observed a clear trend among presence 
or absence of ballooning, but it did not reach statistical significance (1.70+1.93 vs. 
0.90+1.10; p=0.20).  
 
 
Figure 36. MiR-224 plasma expression according to NASH. 
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Finally, both AUROCs were calculated for NASH prediction. First, AUROC 
obtained to predict NASH by using miR-200b was 0.800 [95%CI 0.522-1.000; p=0.43] 
(figure 37). 
 
Figure 37. AUROC for NASH prediction using plasma expression of miR-200b. 
 
Furthermore, AUROC reached for NASH prediction by using miR-224 was 
slightly superior, 0.84 [95% CI 0.694-0.988; p=0.004] (figure 38). 
 
Figure 38. AUROC for NASH prediction using plasma expression of miR-224. 
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DISCUSION 
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NAFLD is the fastest rising cause of hepatic disease worldwide, with no signs of 
decline. Significant progress has been achieved over the past decade regarding the 
pathophysiology and natural history of this disease, discovering that necroinflammation 
and fibrosis are the features that have worse prognosis. These methods have gained 
popularity among clinicians, and given the high prevalence of this disease in general 
population; the need for a definite approach is more urgent.  
Computerised optical analysis of conventional non-contrast-enhanced MR 
images of the liver enables the detection of steatohepatitis by NASHMRI and 
significant fibrosis by FibroMRI in patients suffering from NAFLD. This study 
addresses a critical need for non-invasive markers of both NASH and the associated 
fibrosis. Since fibrosis and steatohepatitis generate appreciable architectural changes in 
liver structure, it would be possible, using this software, to forecast the rate of disease 
progression, to support therapeutic decision-making, and to monitor potential effects of 
therapy. 
Diagnoses of liver diseases have long relied on liver biopsy, despite their high 
intra- and inter-observer variability, discomfort to the patient, and sampling error (32). 
A panel of serum biomarkers to confirm, or rule out, steatohepatitis has remained 
elusive. To date, panels of serum biomarkers for non-invasive assessment have been 
used as surrogate measures. Nevertheless, these methods show many limitations, like 
fluctuations during concomitant disease or lack of reproducibility that could translate to 
false estimation of the disease. Furthermore, these panels are not able to monitor disease 
progression, due to their accuracy being hindered by inflammation. 
One of the major drawbacks of serum biomarkers is its availability for routine 
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clinical use. In an analysis to determine the most cost-effective non-invasive screening 
strategies in a general population vs a high-risk population, that compared NAFLD 
fibrosis Score, TE, ARFI, CK-18 for detecting fibrosis and NASH, it was shown that 
screening with the NAFLD fibrosis score/TE/CK-18 algorithm was the most 
appropriate in high-risk obese or diabetic patients (109). The NashTest, included in 
FibroMax® (110), is a semi-quantitative score with a wide grey zone, and OWLiver® 
(111) accurately predicts steatohepatitis. However, it needs to be analysed in a 
centralised laboratory, and which undermines its accessibility.  
Non-invasive diagnosis of significant fibrosis in NAFLD is also a challenge. 
NAFLD Fibrosis Score was specifically developed for NAFLD. However, it showed a 
wide grey zone in the validation process. Non-invasive markers shunted from hepatitis 
C evaluations have been tested in NAFLD. These include Sydney, FIB-4, Forns and 
APRI indices. However, poor correlations between serum biomarkers of liver fibrosis 
(APRI, FIB-4, AST/ALT ratio, European Liver Panel and Liver stiffness measurement) 
were reported in diabetic patients. The agreement was good on absence of advanced 
liver disease, but not in patients with progressive disorders. FibroMRI was superior to 
NFS and Sydney Index in predicting significant fibrosis. These results would be 
expected because NFS was designed to predict advanced fibrosis from significant 
fibrosis, and Sydney Index was developed in patients with chronic hepatitis C. So these 
scoring systems based on routine lab work, such as FIB-4, NFS, APRI, Forns and 
BARD indexes could be easily calculated at the bedside and can accurately identify 
patients at a higher risk of liver-related complications, death or transplantation. 
However, experts agree that these surrogate biomarkers could rapidly evolve and 
be readily applied to routine clinical practice in the advancing area of NAFLD, 
especially in at-risk populations. Currently, clinical trials are limited by the lack of a 
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non-invasive method with high diagnostic accuracy, reliability, feasibility, cost-
effectiveness and able to measure the responsiveness of treatment.  
Image-based non-invasive methods are receiving increasing attention. They have 
shown a satisfactory correlation with fibrosis staging, but still, need suitable validation 
before being used to guide therapies. For liver fat content quantification, CAP is simple 
and accurate but needs to be implemented with the XL probe to ensure the diagnosis in 
NAFLD patients. Therefore, despite its limitations, US remains the most widely used 
tool in clinical practice. 
Ultrasonography, transient elastography, acoustic radiation force impulse, 
magnetic resonance spectroscopy, magnetic resonance elastography have been 
employed for NASH diagnosis. Ultrasonography has shown 60-94% sensitivity and 84-
95% specificity in hepatic steatosis detection (38); an acceptable first-line steatosis-
screening tool in clinical practice (44) but which cannot distinguish NASH from simple 
steatosis (112). Transient elastography (FibroScan; Echosens, Paris, France) (113) has 
shown a respectable diagnostic accuracy in stratifying advanced fibrosis in NAFLD 
(114). However, transient elastography was found not to be useful in NASH diagnosis 
(115) since >10% of patients could not be assessed because of procedure failures due, 
mainly, to high body mass index (BMI). Hence, thresholds to define advanced fibrosis 
stages remain controversial. Higher scores of stiffness (kPa) to define cirrhosis are 
required compared to cut-offs accepted for viral hepatitis (116, 117). Magnetic 
resonance spectroscopy (MRS) enables the evaluation, in vivo, of liver molecular 
composition, and detects steatosis with high accuracy (118). It is the reference method 
for steatosis but fails in NASH detection. Magnetic resonance elastography (MRE) has 
been shown to be accurate in fibrosis staging (119, 120) but its availability is low in 
most Centres and needs further external validation. The main limitation of these image-
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based methods remains their inability to detect steatohepatitis. Novel developments in 
the MR field, such as gadolinium probes targeted to type-1 collagen, have shown 
excellent preliminary results but still need to be translated into the standard clinical 
setting (121). The scores generated are related to the presence of steatohepatitis or 
fibrosis; the lower the scores, the lower the probability of suffering from steatohepatitis 
or significant fibrosis. The opposite is also valid i.e. the higher the score, the greater the 
risk of displaying steatohepatitis or significant fibrosis. Studies comparing different 
MRI systems manufacturers (such as Siemens vs. Phillips systems) are warranted.  
The next step would be the assessment of a combination of indirect and direct 
markers would perform better in discriminating advanced fibrosis and NASH. The main 
aim is to confirm advanced fibrosis and to decide whether only to monitor patients with 
liver-related complications or detect which patients need in-depth hepatological 
evaluation, including confirmatory biopsy and experimental treatments. 
Although our knowledge is constantly increasing, the number and quality of 
NAFLD studies are limited. Liver biopsy is currently the reference method, but it is 
essential to take into account the inherent limitations of this technique, such as sampling 
and observer variability and safety issues, that could still impair the state of ideal 
surrogate markers. Common non-invasive methods rely on biochemical parameters, as 
well as image-based approaches, but an integrated system including liver biopsy should 
be carried out in order to reach an increased diagnostic accuracy, enabling a more 
efficient and convenient management of these patients, and decreasing the required 
sample size of clinical trials by reducing heterogeneity in population classification. 
Therefore, the ultimate role of non-invasive approaches could be to guide selection of 
patients who require a liver biopsy to stratify disease severity and discriminate who 
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needs treatment. The most important aspects that should be covered are screening, 
diagnosis, prognosis and follow-up at variable time intervals of patients. 
 
FibroMRI accurately predicts significant fibrosis stages. MRI can access deep 
tissue fibrosis staging while analysing the whole liver, and saving on sampling errors. 
As such, it could be useful in the management of liver donors prior to liver 
transplantation (122, 123). Also, it could be tested in liver diseases that share steatosis 
as a major feature such as, for example, viral hepatitis or alcohol-related liver diseases. 
Since ionizing radiation is avoided, this technique would be suitable for harmlessly 
monitoring fibrosis and steatohepatitis progression over time. Progression from simple 
steatosis to NASH and fibrosis in paired liver biopsies 3 to 6 years apart has been 
reported recently (4, 5). Further, in 51 patients who had undergone two liver biopsies 
and scored separately, the results indicated that steatosis, ballooning, inflammation and 
fibrosis appeared not to be equally distributed across the liver. In 21 of 51 cases there 
was one stage difference in the degree of fibrosis, while ballooning was detected in only 
one of the liver biopsies in 9 of 51 cases. As such, close follow-up of the progression of 
liver disease in NAFLD is mandatory, making non-invasive imaging biomarkers the 
optimal approach.  
The main technical limitation of this technique is segmentation error because the 
method is based on an optical analysis of images to quantify differences not perceptible 
to the naked eye. The presence of vessels or different structures in the sample studied 
could be confounding factors resulting in under- or over-estimation of the degree of 
fibrosis, or inflammation. This problem can be resolved, as in the current analysis, by 
excluding areas containing blood vessels, biliary tract, or focal lesions and, as well, all 
samples with >30% pixels outside the segmented area. To avoid manual segmentation 
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errors, this process has been automated, thus allowing the translation of the study to 
different liver diseases. External validation studies are warranted. 
Among the main strengths of the study is the demonstration of its applicability at 
different sites, and using two types of MR devices. The parameters derived from both 
types of machines are standardised. Further, study design was such as to minimise 
observer-related variation, including different measurement conditions that could 
impinge on diagnostic accuracy.  
The expected impact and potential advantages of this method would be 
measured at different levels: 
 (i) Patient´s health and quality of life improvement: These NASHMRI and FibroMRI 
would substitute a test requiring an invasive intervention, such as liver biopsy, by a non-
invasive one that significantly reduces suffering of patients. The number of visits will 
be reduced as the same digital data may be used for several diagnostic techniques, 
improving patient comfort. Moreover, staging of the disease will allow appropriate 
lifestyle intervention and pharmacological treatment so that disease progression is 
slowed or stopped. 
 
 (ii) Patient´s management: Because this method provides a global view of the whole 
liver, it allows better support for comparative analysis and temporal evolution studies. 
Archiving digital images suitable for processing will be possible providing a valuable 
new source of data for the professional. A new patient management algorithm will be 
proposed, that will allow physicians to perform life-style intervention and 
pharmacological treatment after detecting the histological NAFLD features with 
prognostic value.  
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 (iii) Health Systems´ impact: Because non-invasive it provides the ability to screen a 
higher number of patients at risk, rising early diagnosis and clinical efficacy. The main 
benefits are reduced costs (directly and indirectly through the reduction of biopsies, 
hospitalization days and waiting lists), improved processes, better utilization of the 
existing resources (MRI equipment) and improved diagnostic accuracy.  
Further, it was also confirmed that NASH patients have increased hepatic 
mRNA expression of FGF21 and raised serum FGF21 concentration. Moreover, it was 
confirmed the crucial role of PNPLA3 GG-genotype in developing NASH, as well as 
identified a novel risk-conferring SNP, rs838133, associated with increased hazard of 
developing significant fibrosis. These findings are relevant, since NASH and significant 
fibrosis are related to a poor prognosis, and FGF21 has been recently proposed as a 
therapeutic target for NASH.  
Finally, two novel microRNAs candidates were identified, miR-200b-3p and 
miR-224-5p, with a major role in NASH development. Both hepatic and plasma levels 
were raised in NASH patients, showing great potential as non-invasive biomarkers and 
hence, therapeutic targets.  
FGF21 is one of the FGF family factors mainly produced by tissues with high 
metabolic activity, primarily liver, and has been emerged as a key regulator of glucose 
and lipid metabolism, playing an important role in adaptive response to endoplasmic 
reticulum stress (124). Liver FGF21 mRNA expression was already found significantly 
increased in simple steatosis patients; nevertheless, NASH patients showed higher 
serum FGF21 levels but not increased hepatic mRNA. 
It has been described that exercise, and caloric restriction prevents NAFLD by 
reducing both mRNA FGF21 expression and protein circulating levels in animal 
models  (125), suggesting the potential implication of lifestyle modifications into 
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medium or long-term in FGF21 expression. In vivo suppression of hepatic FGF21 
expression with shRNA adenovirus showed that induction of FGF21 is required in the 
liver for entirely regulation of its metabolism in response to a high-fat low-carbohydrate 
ketogenic diet on mice (126). Recently, in a cohort of aging mice that simulates the 
slow onset of NAFLD fed with medium-fat diet for 28 months, they observed that up-
regulated Fgf21 plasma levels were implied to be a protective response to the NAFLD-
induced unfavourable outcomes (127). 
FGF21 has received considerable attention due to its anti-diabetic effect in 
rodent models, being found paradoxically elevated in the setting of impaired glucose 
tolerance, together with the cluster of features presented in metabolic syndrome, such as 
obesity, hypertension and coronary heart disease. Additionally, plays a significant role 
in the pathogenic elements of NASH, through the accumulation of inactivated fatty 
acids, resulting in lipotoxic damage (128). These data suggest that raised FGF21 may 
occur as a compensatory response to offset metabolic disturbances.  
A potential role for FGF21 in cardiovascular disease has also been pointed out. 
Fgf21 knockout mice developed enhanced signs of cardiac dysfunction, and this effect 
was reversed in vivo with FGF21 treatment (129). In agreement with animal studies, 
serum FGF21 levels were increased in patients suffering from atherosclerotic disease 
measured by ankle-brachial index (130), and serum FGF21 levels have also been 
identified as an independent risk factor for coronary artery disease (131). Finally, 
abnormal levels of serum FGF21 have been found associated with increased risk for all-
causes and cardiovascular disease mortality (132). 
In human beings, LY2405319, an FGF21 analogue, produced significant 
improvements on selected metabolic disorders, such as dyslipidaemia, obesity and 
insulinemia, indicating that FGF21 is bioactive in humans and could serve as a 
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therapeutic option (75). Furthermore, different approaches are currently investigated, 
such as FGF21 conjugation with polyethylene glycol in order to increase its half-life, 
enhancing its anti-diabetic effects in rodents (133). Recently it was reported that 
simvastatin use reduces hepatic and circulating Fgf21 levels in mice (134), and also 
acute exercise increases FGF21 in both serum and metabolic organs (135). 
Considering that intravenous dose of FGF21 improves insulin resistance, 
decreases fasting glucose and reverses steatosis in NAFLD animal models (136), 
increased FGF21 gene liver expression detected in the current study, could be explained 
as a compensatory response to oxidative stress and glucose-lipid homeostasis disorders 
(62). FGF21 could correct multiple metabolic parameters in vitro and in vivo by 
inducing autophagy (137) and may be part of a strategy to combat hepatic steatosis and 
inflammation.  
In a genome-wide meta-analysis performed among 33,000 participants, 
rs838133 variant located in FGF21 gene was found associated with decreased protein 
intake and increased carbohydrate consumption, potentially determining dietary 
macronutrient intake and subsequently conditioning NAFLD condition (23). Further, 
other four SNPs were explored in non-diabetic subjects and compared with FGF21 
protein levels, in ultrasonography NAFLD-diagnosed patients, finding an association 
between rs499765 and FGF21 serum levels, and rs838133 was found associated with 
AST levels (138). 
Consistently with these hypotheses, we found upregulation of FGF21 at various 
levels, such as hepatic expression, circulating levels and increased risk of fibrosis 
conferred by bearing A-allele of rs838133. FGF21 plays multiple and vital roles in 
regulating energy homeostasis and glucose-lipid metabolism, and currently, 
mechanisms that underlie this association with NAFLD are being cleared. Recently 
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reported data suggest that FGF21 could be either a drug candidate with 
pharmacological and beneficial effects or a clinically useful biomarker for early 
NAFLD diagnosis, but deeper functional studies are warranted to explore further the 
physiological functions and regulation of FGF21 in human beings. 
Altered epigenetics patterns could distinguish between NAFLD stages, but a 
better understanding of the molecular mechanisms is mandatory to identify reliable 
biomarkers and effective treatments. Among epigenetic mechanisms, miRNAs occupy a 
top position, because their disturbances present potential prognostic and diagnostic, and 
the ability to be therapeutic targets.  
Certain miRNAs are stable and easily measurable in serum or plasma and 
therefore hold the potential to be ideal disease biomarkers. Aberrant microRNA profiles 
have been previously reported in a broad spectrum of liver diseases. Promising results 
have been observed using circulating miRNAs as predictors of several outcomes. One 
of the main advantages as non-invasive biomarkers is their high stability in body fluids, 
enabling their use as non-invasive diagnostic and prognostic tools. 
In this exploratory study, two targets were identified with potential to be non-
invasive biomarkers, miR-200b-3p and miR-224-5p. Previously miR-200b has been 
related to hepatocellular carcinoma, acting by downregulation of the expression levels 
of DNA methyltransferase 3a (DNMT 3a) (139). Moreover, it has been detected an 
overexpression of this microRNA in tissue of primary intrahepatic cholangiocarcinoma 
patients, but not in plasma samples (140).  
 
MiR-224 has also demonstrated a significant role by targeting cell proliferation, 
migration, invasion and anti-apoptotic properties in hepatocellular carcinoma by 
directly interacting with several genes (141). It has also been found overexpressed in 
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hepatocellular carcinoma vs normal samples (142), so different studies have been 
attributed it oncogenic properties, revealing that autophagy selectively regulates miR-
224 expression through an autophagosome-mediated degradation system (143). 
Considering the tight relationship between autophagy and NASH, this could be a 
potential explanation of its overexpression in both liver and serum samples. 
These novel results show how both microRNAs can distinguish between NASH 
and steatosis simple patients. The main limitation is the sample size, but a larger 
prospective study is now ongoing to increase the number of patients in both categories. 
Especially for miR-224, its plasma levels are able to accurately distinguish between 
both, reaching an AUROC of 0.84 in diagnosing NASH. If these results are confirmed 
in a larger study, this miRNA could serve as adjuncts in non-invasive diagnosis.  
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ü Combined use of imaging biomarkers, NASHMRI and FibroMRI, could be 
useful in diagnosing steatohepatitis and significant fibrosis in patients with 
suspected NAFLD. Those imaging biomarkers offer clear advantages above 
liver biopsy since they are innocuous, less traumatic for the patient, and cheaper. 
Analysing the whole liver using user-friendly software would be ideal for close 
monitoring over time, and for extensive implementation for screening large 
numbers of at-risk patients. Clear disease staging on severity would provide 
support in clinical decision-making.  
 
ü Both hepatic and circulating levels of FGF21 were found increased in NASH, 
one of the most aggressive conditions of NAFLD. Further, bearing PNPLA3 GG 
genotype and carrying A-allele of FGF21 variant confer susceptibility to NASH 
and significant fibrosis development 
 
ü Two novel microRNAs were found overexpressed in NASH condition, not just 
in liver but also in plasma, conferring them potential as non-invasive 
biomarkers. 
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